Panaji, 5th March, 1971 (Phalguna 14, 1892) SERIES I No. 49

OFFICIAL GAZETTE

GOVERNMENT OF GOA, DAMAN AND DIU

GOVERNMENT OF GOA, DAMAN AND DIU

Revenue Department

Notification

RD/LRC/57/71

In exercise of the powers conferred by sub-section (3) of Section 1 of the Goa, Daman and Diu Land Revenue Code, 1968 (Act No. 9 of 1969), the Administrator of Goa, Daman and Diu hereby appoints the first day of March, 1971 as the date on which the provisions of Sections 4 to 198 and 200 to 201 of the said Code, shall come into force in the Union Territory of Goa, Daman and Diu.

By order and in the name of the Administrator of Goa, Daman and Diu.

J. C. Almeida, Secretary (Revenue).

Panaji, 27th February, 1971.

Local Self Government Department

Notification

No. 5-8-69-LSG

Read: 1. Government Notification No. 5-8-70-LSG dated 27-1-70.

2. Letter No. 8/4/69. SCT. II dated 15-1-71 from the Under Secretary to the Government of India, Department of Social Welfare, New Delhi.

Under Government Notification cited at Sl. No. 1 above, the Administrator of Goa, Daman and Diu had sanctioned the scheme for grant of loan-cum-subsidy to persons belonging to Scheduled Castes and Scheduled Tribes for purchase of milch cattle.

Under clause 1 of the scheme the total amount of assistance including both the loan and subsidy was not to exceed Rs. 500/-. The Administrator of Goa, Daman and Diu with the approval of the Government of India is now pleased to raise the limit of the total amount of assistance of Rs. 500/- to Rs. 1,000/-, with immediate effect.

By order and in the name of the Administrator of Goa, Daman and Diu.

V. Sardessai, Under Secretary (Revenue).

Panaji, 15th February, 1971.

Development Department 'A'

Notification

CDB/COOP/1167/68-71

The following rules for the establishment and use of Agricultural Credit Stabilisation Fund at the level of Apex Cooperative Bank in the Union Territory of Goa, Daman and Diu, as approved by Government of India, under their letter No. 3-3/69-Credit dated 8-10-69 are hereby notified in the Government Gazette.

By order and in the name of the Administrator of Goa, Daman and Diu.

F. A. Figueiredo, Under Secretary (Development).

Panaji, 15th February, 1971.

Rules for the establishment and use of Agricultural Credit Stabilisation Fund at the level of Apex Cooperative Bank in the Union Territory of Goa, Daman and Diu.

1. Aims and objects:

The Agricultural Credit Stablisation Fund is intended to facilitate the conversion of short term loans for agricultural purposes into medium-term loans, in circumstances in which total or partial failure of crops resulting from widespread natural calamity renders the repayment of such short-term loans impossible without dislocation of the structure and without hardship to individual agriculturists. The principles and procedure set out below shall govern the establishment and utilisation of the fund.

2. Establishment of Fund:

Agricultural Credit Stabilisation Fund (hereinafter called the "Fund") shall be maintained at the level of the Apex Cooperative Bank, namely, in the Goa State Cooperative Bank (hereinafter called the "Bank") which functions as the Apex Bank in this Territory.

3. Resources for establishing and maintaining fund:

The fund shall be constituted and maintained by the Bank by crediting contributions from different sources as indicated below: —

(a) Outright grants received for the purpose from the Government of Goa, Daman and Diu.

(b) Loans received for the purpose from the Government of Goa, Daman and Diu.

(c) Annual appropriation of 15% of net profits of the Bank.

(d) Transfer of dividend over and above 3 per cent payable to the Government on its share holding in the Bank.

(e) Credit of interest at 3% per annum on the balance to the credit of the fund as at the commencement of the year; and

(f) Transfer of any other sums which the Bank may contribute or receive for the purpose.

4. **Investment of Fund:**

(a) The entire fund shall be invested in Government or Trustee securities.

(b) The income from the investment of the Fund in loans, in Government or Trustee securities shall be appropriated by the Bank to its profit and loss account.

(c) The Bank shall pay to the Fund interest at 3% per annum on the amount to the credit of the Fund at the commencement of the year.

(d) Any depreciation in the investments of the fund shall be made good by the Bank concerned out of its general income.

5. **Procedure for determining the circumstances for the use of funds and terms and conditions of operation:**

A. *Primary Society Level: —*

1) On the occurrence of a natural calamity such as drought, floods cyclone, attack of pests or locusts, resulting in failure of crops and before harvesting of such crops standing in the fields, every individual member of a primary agricultural credit society who is not in a position to repay the short term loan taken by him from the society and who desires that the short term loan due from him be converted into a medium term loan, shall apply in writing to that effect to his society, providing such particulars regarding estimated value of his crop, the amount which he may be able to repay, etc. as may be prescribed.

2) As soon as possible thereafter, a General Body Meeting of the Society shall be convened to consider the requests for conversions or extensions and to determine the extent and period for which conversions or extensions may be granted and to pass necessary resolution in that behalf.

3) Every primary agricultural credit society which seeks conversion of short-term loans for agricultural purposes into medium term loans will be required to make an application to that effect to the Bank supported by a resolution of the General Body.

4) Only on the receipt of advice in writing from the Bank that the conversion has been granted shall the primary agricultural credit society proceed to take necessary action as follows: —

5) Short-term loans upto Rs. 1000/- may be converted into medium term loans against personal surety, loan between Rs. 1001/- to Rs. 1500/- against charge on land and all loans above Rs. 1500/- shall be secured by mortgage of land.

6) The ultimate borrowers shall be required to furnish fresh time promissory notes in favour of the society which shall correspond to the plan of repayment of medium-term loans and such undertaking in regard to the sale of his produce through a marketing cooperative society as may be prescribed by the credit society.

7) Where a borrower is unable to offer a charge on land, or mortgage his property as the case may be, owing to encumbrances on land or property for other prior borrowings from Co-operative agencies, the condition in (5) above may be dispensed with, and conversion allowed, as a special case against two personal sureties.

8) The short term loan account of the borrower shall be credited with the amount of principal due by a corresponding debit to a medium-term loan account to be opened.

9) All recoveries in respect of medium-term loan thus advanced for conversion shall be credited straightaway to the respective loan accounts.

10) All sums received in repayment of converted medium-term loan granted by the bank shall be remitted to the Bank without any delay.

11) Separate accounts shall be maintained in respect of such converted medium-term loans received or advanced by the society so as to destinguish them from other loans received or granted by it.

B. *Bank Level:*

1) The State Cooperative Bank shall determine, on scrutiny of the applications received and on such investigation as it may undertake, the amount of short-term loans which, in its opinion may be justifiably converted into medium-term loans.

2) The Bank shall take steps to move the revenue authorities to conduct annawari proceedings and to furnish a certificate regarding the annawari classification of crops expeditiously. The Bank shall proceed to sanction conversion facility only if the annawari is certified by the revenue authorities in respect of the crops in the villages covered by the societies whose loans are to be converted, falls within the classification of total or partial failure of crops or at any rate is below 6 annas or its equivalent if expressed in some other form.

3) The Bank shall be deemed to be in a position to meet 15% of the amount of the short term dues intended to be converted into medium term loans from out of drawable resources of the "funds" maintained by it and or out of its other resources.

4) If the bank cannot sanction such conversion in full from the resources available from its Stabilization Fund, it shall forward the applications of the affiliated societies to the Reserve Bank of India and at the same time shall itself apply, in the prescribed form, to the Reserve Bank alongwith a resolution of its Board of Directors seeking from the Reserve Bank conversion facilities for the amount of short term loans due to the Reserve Bank which cannot

be converted from its Stabilization Fund. The application to the Reserve Bank of India shall be routed through the Registrar of Cooperative Societies, who should secure and forward to the Reserve Bank the willingness of the Government of India to guarantee the Reserve Bank in respect of repayment of principal and payment of interest, the loan recommended by him to the Reserve Bank for sanction out of its National Agricultural Credit (Stabilization) Fund. He shall also arrange to furnish the Reserve Bank the Government of India's Guarantee Deed in the prescribed form.

5) On the Reserve Bank sanctioning the conversion of loans the Bank may approach the Manager, Reserve Bank of India at the office of the Reserve Bank where its principal account is maintained and furnish the necessary time promissory notes of the affiliated societies duly countersigned.

6) On the Manager Reserve Bank of India carrying out the adjustments for conversion of short-term loans into medium-term loans, corresponding action will be taken by the bank to convert the short term loans of the affiliated societies into medium term loans by crediting their short term loan accounts by the amount of conversion sanctioned by it by debit to the fresh medium term loan account.

7) Separate accounts shall be maintained by the Bank in respect of loans received or given by it for purpose of conversion so as to distinguish them from all other loans received or given by it.

8) All repayments in respect of converted loans shall be remitted without delay to the Reserve Bank of India and corresponding credit furnished in the converted medium-term loans accounts.

9) The bank shall be free to pledge the securities representing the investment of its Stabilisation Fund to the extent necessary, for the purpose of raising resources required for granting conversion facilities.

10) The Fund shall be deemed as fully utilised as soon as the overdraft facility enjoyed by the Bank against the Government and Trustee securities of the Fund is fully utilised.

6. Reports and returns.

The Bank shall submit such Reports and returns regarding the utilisation and investment of the funds as the Registrar of Cooperative Societies, may direct from time to time.

Public Health Department

Notification

A-9/70-DHS/10397

In pursuance of article 2 of World Health Organisation, Regulations regarding nomenclature (including the compilations and publication of statistics) with respect to diseases and causes of death, the Lt. Governor of Goa, Daman and Diu, hereby notifies adoption of revised International Classification of Diseases appended hereto, with effect from 1-1-1971.

This supersedes earlier nomenclatures regarding classifications of deaths and causes of deaths issued under Portarias no. 13.748 dated 23-11-1951 and no. 7069 dated 5-11-1957.

By order and in the name of the Administrator of Goa, Daman and Diu.

S. R. Sawant, Under Secretary (Health).

Panaji, 21st January, 1971.

INTERNATIONAL CLASSIFICATION OF DISEASES

(Eighth Revision)

LIST OF THREE-DIGIT CATEGORIES (With A List Groupings)

I. INFECTIVE AND PARASITIC DISEASES

Intestinal infectious diseases (000-009)

000	Cholera	(A 1)
001	Typhoid fever	(A 2)
002	Paratyphoid fever	(A 3)
003	Other Salmonella infections	(A 3)
004	Bacillary dysentery	(A 4)
005	Food poisoning (bacterial)	(A 21)
006	Amoebiasis	(A 4)
007	Other protozoal intestinal diseases	(A 21)
008	Enteritis due to other specified organism	(A 5)
009	Diarrhoeal disease	(A 5)

Tuberculosis (010-019)

010	Silicotuberculosis	(A 6)
011	Pulmonary tuberculosis	(A 6)
012	Other respiratory tuberculosis	(A 6)
013	Tuberculosis of meninges and central nervous system	(A 7)
014	Tuberculosis of intestines, peritoneum and mesenteric glands	(A 8)
015	Tuberculosis of bones and joints	(A 9)
016	Tuberculosis of genito-urinary system	(A 10)
017	Tuberculosis of other organs	(A 10)
018	Disseminated tuberculosis	(A 10)
019	Late effects of tuberculosis	(A 10)

Zoonotic bacterial diseases (020-027)

020	Plague	(A 11)
021	Tularaemia	(A 21)
022	Anthrax	(A 12)
023	Brucellosis	(A 13)
024	Glanders	(A 21)
025	Melioidosis	(A 21)
026	Rat-bite fever	(A 21)
027	Other Zoonotic bacterial disases	(A 21)

Other bacterial diseases (030-039)

030	Leprosy	(A 14)
031	Other diseases due to mycobacteria	(A 21)
032	Diphtheria	(A 15)
033	Whooping cough	(A 16)

034 Streptococcal sore throat and scarlet fever (A 17)
035 Erysipelas (A 18)
036 Meningococcal infection (A 19)
037 Tetanus (A 20)
038 Septicaemia (A 21)
039 Other bacterial diseases (A 21)

Poliomyelitis and other enterovirus diseases of central nervous system (040-046)

040 Acute paralytic poliomyelitis specified as bulbar (A 22)
041 Acute poliomyelitis with other paralysis (A 22)
042 Acute non-paralytic poliomyelitis (A 22)
043 Acute poliomyelitis, unspecified (A 22)
044 Late effects of acute poliomyelitis (A 23)
045 Aseptic meningitis due to enterovirus (A 29)
046 Other enterovirus diseases of central nervous system (A 29)

Viral diseases accompanied by exanthem (050-057)

050 Smallpox (A 24)
051 Cowpox (A 29)
052 Chickenpox (A 29)
053 Herpes zoster (A 29)
054 Herpes simplex (A 29)
055 Measles (A 25)
056 Rubella (A 29)
057 Other viral exanthem (A 29)

Arthropod-borne viral diseases (060-068)

060 Yellow fever (A 26)
061 Dengue (A 29)
062 Mosquito-borne viral encephalitis (A 27)
063 Tick-borne viral encephalitis (A 27)
064 Viral encephalitis transmitted by other arthropods (A 27)
065 Viral encephalitis, unspecified (A 27)
066 Late effects of viral encephalitis (A 29)
067 Arthropod-borne haemorrhagic fever (A 29)
068 Other arthropod-borne viral diseases (A 29)

Other viral diseases (070-079)

070 Infectious hepatitis (A 28)
071 Rabies (A 29)
072 Mumps (A 29)
073 Psittacosis (A 29)
074 Specific diseases due to Coxsackie virus (A 29)
075 Infectious mononucleosis (A 29)
076 Trachoma, active (A 29)
077 Late effects of trachoma (A 29)
078 Other viral diseases of the conjunctiva (A 29)
079 Other viral diseases (A 29)

Rickettsioses and other arthropod-borne diseases (080-089)

080 Epidemic louse-borne typhus (A 30)
081 Other typhus (A 30)
082 Tick-borne rickettsiosis (A 30)
083 Other rickettsioses (A 30)
084 Malaria (A 31)
085 Leishmaniasis (A 44)
086 American trypanosomiasis (A 32)
087 Other trypanosomiasis (A 32)
088 Relapsing fever (A 33)
089 Other arthropod-borne diseases (A 44)

Syphilis and other venereal diseases (090-099)

090 Congenital syphilis (A 34)
091 Early syphilis, symptomatic (A 35)
092 Early syphilis latent (A 37)
093 Cardiovascular syphilis (A 37)
094 Syphilis of central nervous system (A 36)
095 Other forms of late syphilis with symptoms (A 37)
096 Late syphilis, latent (A 37)
097 Other syphilis and not specified (A 37)
098 Gonococcal infection (A 38)
099 Other veneral disease (A 44)

Other spirochaetal diseases (100-104)

100 Leptospirosis (A 44)
101 Vincent's angina (A 44)
102 Yaws (A 44)
103 Pinta (A 44)
104 Other spirochaetal infection (A 44)

Mycoses (110-117)

110 Dermatophytosis (A 44)
111 Dermatomycosis, other and unspecified (A 44)
112 Moniliasis (A 44)
113 Actinomycosis (A 44)
114 Coccidiomycosis (A 44)
115 Histoplasmosis (A 44)
116 Blastomycosis (A 44)
117 Other systemic mycosis (A 44)

Helminthiases (120-129)

120 Schistosomiasis (bilharziasis) (A 39)
121 Other trematode infection (A 43)
122 Hydatidosis (A 40)
123 Other cestode infection (A 43)
124 Trichiniasis (A 43)
125 Filarial infection (A 41)
126 Ancylostomiasis (A 42)
127 Other intestinal helminthiasis (A 43)
128 Other and unspecified helminthiasis (A 43)
129 Intestinal parasitism,unspecified (A 43)

Other infective and parasitic Diseases (130-136)

130 Toxoplasmosis (A 44)
131 Trichomoniasis urogenitalis (A 44)
132 Pediculosis (A 44)
133 Acariasis (A 44)
134 Other infestation (A 44)
135 Sarcoidosis (A 44)
136 Other and unspecified infective and parasitic diseases (A 44)

II NEOPLASMS

Malignant neoplasm of buccal cavity and pharynx (140-149)

140 Malignant neoplasm of lip (A 45)
141 Malignant neoplasm of tongue (A 45)
142 Malignant neoplasm of salivary gland (A 45)
143 Malignant neoplasm of gum (A 45)
144 Malignant neoplasm of floor of mouth (A 45)
145 Malignant neoplasm of other and unspecified parts of mouth (A 45)
146 Malignant neoplasm of oropharynx (A 45)
147 Malignant neoplasm of nasopharynx (A 45)
148 Malignant neoplasm of hypopharnx (A 45)
149 Malignant neoplasm of pharynx, unspecified (A 45)

Malignant neoplasm of digestive organs and peritoneum (150-159)

150	Malignant neoplasm of oesophagus	(A 46)
151	Malignant neoplasm of stomach	(A 47)
152	Malignant neoplasm of small intestine, including duodenum	(A 48)
153	Malignant neoplasm of large intestine, except rectum	(A 48)
154	Malignant neoplasm of rectum and rectosigmoid junction	(A 49)
155	Malignant neoplasm of liver and intrahepatic bile ducts, specified as primary	(A 58)
156	Malignant neoplasm of gallbladder and bile ducts	(A 58)
157	Malignant neoplasm of pancreas	(A 58)
158	Malignant neoplasm of peritoneum and retroperitoneal tissue	(A 58)
159	Malignant neoplasm of unspecified digestive organs	(A 58)

Malignant neoplasm of respiratory system (160-163)

160	Malignant neoplasm of nose, nasal cavities middle ear and accessory sinuses	(A 58)
161	Malignant neoplasm of larynx	(A 50)
162	Malignant neoplasm of trachea, bronchus and lung	(A 51)
163	Malignant neoplasm of other and unspecified respiratory organs	(A 58)

Malignant neoplasm of bone, connective tissue, skin and breast (170-174)

170	Malignant neoplasm of bone	(A 52)
171	Malignant neoplasm of connective and other soft tissue	(A 58)
172	Malignant melanoma of skin	(A 53)
173	Other malignant neoplasm of skin	(A 53)
174	Malignant neoplasm of breast	(A 54)

Malignant neoplasm of genito-urinary organs (180-189)

180	Malignant neoplasm of cervix uteri	(A 55)
181	Chorionepitheliomo	(A 56)
182	Other malignant neoplasm of uterus	(A 56)
183	Malignant neoplasm of ovary, fallopian tube and broad ligament	(A 58)
184	Malignant neoplasm of other and unspecified female genital organs	(A 58)
185	Malignant neoplasm of prostate	(A 57)
186	Malignant neoplasm of testis	(A 58)
187	Malignant neoplasm of other and unspecified male genital organs	(A 58)
188	Malignant neoplasm of bladder	(A 58)
189	Malignant neoplasm of other and unspecified urinary organs	(A 58)

Malignant neoplasm of other and unspecified sites (190-199)

190	Malignant neoplasm of eye	(A 58)
191	Malignant neoplasm of brain	(A 58)
192	Malignant neoplasm of other parts of nervous system	(A 58)
193	Malignant neoplasm of thyroid gland	(A 54)
194	Malignant neoplasm of other endocrine glands	(A 58)
195	Malignant neoplasm of illdefined sites	(A 58)
196	Secondary and unspecified malignant neoplasm of lymph nodes	(A 58)
197	Secondary malignant neoplasm of respiratory and digestive systems	(A 58)
198	Other secondary malignant neoplasm	(A 58)
199	Malignant neoplasm without specification of site	(A 58)

Neoplasms of lymphatic and haematopoietic tissue (200-209)

200	Lymphosarcoma and reticulum-cell sarcoma	(A 60)
201	Hodgkin's disease	(A 60)
202	Other neoplasms of lymphoid tissue	(A 60)
203	Multiple myeloma	(A 60)
204	Lymphatic leukaemia	(A 59)
205	Myeloid leukaemia	(A 59)
206	Monocytic leukaemia	(A 59)
207	Other and unspecified leukaemia	(A 59)
208	Polycythaemia vera	(A 60)
209	Myelofibrosis	(A 60)

Benign neoplasms (210-228)

210	Benign neoplasm of buccal cavity and pharynx	(A 61)
211	Benign neoplasm of other parts of digestive system	(A 61)
212	Benign neoplasm of respiratory system	(A 61)
213	Benign neoplasm of bone and cartilage	(A 61)
214	Lipoma	(A 61)
215	Other benign neoplasm of muscular and connective tissue	(A 61)
216	Benign neoplasm of skin	(A 61)
217	Benign neoplasm of breast	(A 61)
218	Uterine fibroma	(A 61)
219	Other benign neoplasm of uterus	((A61)
220	Benign neoplasm of ovary	(A 61)
221	Benign neoplasm of other female genital organs	(A 61)
222	Benign neoplasm of male genital organs	(A 61)
223	Benign neoplasm of kidney and other urinary organs	(A 61)
224	Benign neoplasm of eye	(A 61)
225	Benign neoplasm of brain and other parts of nervous system	(A 61)
226	Benign neoplasm of endocrine glands	(A 61)
227	Haemangioma and lymphangioma	(A 61)
228	Benign neoplasm of other and unspecified organs and tissues	(A 61)

Neoplasm of unspecified nature (230-239)

230	Neoplasm of unspecified nature of digestive organs	(A 61)
231	Neoplasm of unspecified nature of respiratory organs	(A 61)
232	Neoplasm of unspecified nature of skin and musculoskeletal system	(A 61)
233	Neoplasm of unspecified nature of breast	(A 61)
234	Neoplasm of unspecified nature of uterus	(A 61)
235	Neoplasm of unspecified nature of ovary	(A 61)
236	Neoplasm of unspecified nature of other female genital organs	(A 61)
237	Neoplasm of unspecified nature of other genito-urinary organs	(A 61)
238	Neoplasm of unspecified nature of eye, brain and other parts of nervous system	(A 61)
239	Neoplasm of unspecified nature of other and unspecified organs	(A 61)

III. ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES

Diseases of thyroid gland (240-246)

240	Simple goitre	(A 62)
241	Non-toxic nodular goitre	(A 62)
242	Thyrotoxicosis with or without goitre	(A 63)
243	Cretinism of congenital origin	(A 66)
244	Myxoedema	(A 66)
245	Thyroiditis	(A 66)
246	Other diseases of thyroid gland	(A 66)

Diseases of other endocrine glands (250-258)

250	Diabetes mellitus	(A 64)
251	Disorders of pancreatic internal secretion other than diabetes mellitus	(A 66)
252	Diseases of parathyroid gland	(A 66)
253	Diseases of pituitary gland	(A 66)
254	Diseases of thymus gland	(A 66)
255	Diseases of adrenal glands	(A 66)
256	Ovarian dysfunction	(A 66)
257	Testicular dysfunction	(A 66)
258	Polyglandular dysfunction and other diseases of endocrine glands	(A 66)

Avitaminoses and other nutritional deficiency (260-269)

260	Vitamin A deficiency	(A 65)
261	Thiamine deficiency	(A 65)
262	Niacin deficiency	(A 65)
263	Other vitamin B deficiency	(A 65)
264	Ascorbic acid deficiency	(A 65)
265	Vitamin D deficiency	(A 65)
266	Other vitamin deficiency states	(A 65)
267	Protein malnutrition	(A 65)
268	Nutritional marasmus	(A 65)
269	Other nutritional deficiency	(A 65)

Other metabolic diseases (270-279)

270	Congenital disorders of amino-acid metabolism	(A 66)
271	Congenital disorders of carbohydrate metabolism	(A 66)
272	Congenital disorders of lipid metabolism	(A 66)
273	Other unspecified congenital disorders of metabolism	(A 66)
274	Gout	(A 66)
275	Plasma protein abnormalities	(A 66)
276	Amyloidosis	(A 66)
277	Obesity not specified as of endocrine origin	(A 66)
278	Other hyperalimentation	(A 66)
279	Other and unspecified metabolic diseases	(A 66)

IV. DISEASES OF BLOOD AND BLOOD-FORMING ORGANS

280	Iron deficiency anaemias	(A 67)
281	Other deficiency anaemias	(A 67)
282	Hereditary haemolytic anaemias	(A 67)
283	Acquired haemolytic anaemias	(A 67)
283	Acquired haemolytic anaemias	(A 67)
284	Aplastic anaemia	(A 67)
285	Other and unspecified anaemias	(A 67)
286	Coagulation defects	(A 68)
287	Purpura and other haemorrhagic conditions	(A 68)
288	Agranulocystosis	(A 68)
289	Other diseases of blood and blood-forming organs	(A 68)

V. MENTAL DISORDERS

Psychoses (290-299)

290	Senile and pre-senile dementia	(A 69)
291	Alcoholic psychosis	(A 69)
292	Psychosis associated with intracranial infection	(A 69)
293	Psychosis associated with other cerebral condition	(A 69)
294	Psychosis associated with other physical condition	(A 69)
295	Schizophrenia	(A 69)
296	Affective psychoses	(A 69)
297	Paranoid states	(A 69)
298	Other psychoses	(A 69)
299	Unspecified psychosis	(A 69)

Neuroses, personality disorders and other non-psychotic mental disorders (300-309)

300	Neuroses	(A 70)
301	Personality disorders	(A 70)
302	Sexual deviation	(A 70)
303	Alcoholism	(A 70)
304	Drug dependence	(A 70)
305	Physical disorders of presumably psychogenic origin	(A 70)
306	Special symptoms not elsewhere classified	(A 70)
307	Transient situational disturbances	(A 70)
308	Behaviour disorders of childhood	(A 70)
309	Mental disorders not specified as Psychotic associated with physical conditions	(A 70)

Mental retardation (310-315)

310	Borderline mental retardation	(A 71)
311	Mild mental retardation	(A 71)
312	Moderate mental retardation	(A 71)
313	Severe mental retardation	(A 71)
314	Profound mental retardation	(A 71)
315	Unspecified mental retardation	(A 71)

VI. DISEASES OF THE NERVOUS SYSTEM AND SENSE ORGANS

Inflammatory diseases of central nervous system (320-324)

320	Meningitis	(A 72)
321	Phlebitis and thrombophlebitis of intracranial venous sinuses	(A 79)
322	Intracranial and intraspinal abscess	(A 79)
323	Encephalitis, myelitis, and encephalomyelitis	(A 79)
324	Late effects of intracranial abscess or pyogenic infection	(A 79)

Hereditary and familial diseases of nervous system (330-333)

330	Hereditary neuromuscular disorders	(A 79)
331	Hereditary diseases of the striato-pallidal system	(A 79)
332	Hereditary ataxia	(A 79)
333	Other hereditary and familial diseases of nervous system	(A 79)

Other diseases of central nervous system (340-349)

340	Multiple sclerosis	(A 73)
341	Other demyelinating diseases of central nervous system	(A 79)
342	Paralysis agitans	(A 79)
343	Cerebral spastic infantile paralisis	(A 79)
344	Other cerebral paralysis	(A 79)
345	Epilepsy	(A 74)
346	Migraine	(A 79)
347	Other diseases of brain	(A 79)
348	Motor neurone disease	(A 79)
349	Other diseases of spinal cord	(A 79)

Diseases of nerves and peripheral ganglia (350-358)

350	Facial paralysis	(A 79)
351	Trigeminal neuralgia	(A 79)
352	Brachial neuritis	(A 79)
353	Sciatica	(A 79)
354	Polyneuritis and polyradiculitis	(A 79)
355	Other and unspecified forms of neuralgia and neuritis	(A 79)
356	Other diseases of cranial nerves	(A 79)
357	Other diseases of peripheral nerves except autonomic	(A 79)
358	Diseases of peripheral autonomic nervous system	(A 79)

Inflammatory diseases of the eye (360-369)

360	Conjunctivitis and ophthalmia	(A 75)
361	Blepharitis	(A 75)
362	Hordeolum	(A 75)
363	Keratitis	(A 75)
364	Iritis	(A 75)
365	Choroiditis	(A 75)
366	Other inflammation of uveal tract	(A 75)
367	Inflammation of optic nerve and retina	(A 75)
368	Inflammation of lacrimal glands and ducts	(A 75)
369	Other inflammatory diseases of eye	(A 75)

Other diseases and conditions of eye (370-379)

370	Refractive errors	(A 79)
371	Corneal opacity	(A 79)
372	Pterygium	(A 79)
373	Strabismus	(A 79)
374	Cataract	(A 76)
375	Glaucoma	(A 77)
376	Detachment of retina	(A 79)
377	Other diseases of retina and optic nerve	(A 79)
378	Other diseases of eye	(A 79)
379	Blindness	(A 79)

Diseases of the ear and mastoid process (380-389)

380	Otitis externa	(A 79)
381	Otitis media without mention of mastoiditis	(A 78)
382	Otitis media with mastoiditis	(A 78)
383	Mastoiditis without mention of otitis media	(A 78)
384	Other inflammatory diseases of ear	(A 79)
385	Meniere's disease	(A 79)
386	Otosclerosis	(A 79)
387	Other diseases of ear and mastoid process	(A 79)
388	Deaf mutism	(A 79)
389	Other deafness	(A 79)

VII. DISEASES OF THE CIRCULATORY SYSTEM

Active rheumatic fever (390-392)

390	Rheumatic fever without mention of heart involvement	(A 80)
391	Rheumatic fever with heart involvement	(A 80)
392	Chorea	(A 80)

Chronic rheumatic heart disease (393-398)

393	Diseases of pericardium	(A 81)
394	Diseases of mitral valve	(A 81)
395	Diseases of aortic valve	(A 81)
396	Diseases of mitral and aortic valves	(A 81)
397	Diseases of other endocardial structures	(A 81)
398	Other heart disease, specified as rheumatic	(A 81)

Hypertensive disease (400-404)

400	Malignant hypertension	(A 82)
401	Essential benign hypertension	(A 82)
402	Hypertensive heart disease	(A 82)
403	Hypertensive renal disease	(A 82)
404	Hypertensive heart and renal disease	(A 82)

Ischaemic heart disease (410-414)

410	Acute myocardial infraction	(A 83)
411	Other acute and sub-acute forms of ischaemic heart disease	(A 83)
412	Chronic ischaemic heart disease	(A 83)
413	Angina pectoris	(A 83)
414	Asymptomatic ischaemic heart disease	(A 83)

Other forms of heart disease (420-429)

420	Acute pericarditis, non-rheumatic	(A 84)
421	Acute and sub-acute endocarditis	(A 84)
422	Acute myocarditis	(A 84)
423	Chronic disease of pericardium, non-rheumatic	(A 84)
424	Chronic disease of endocardium	(A 84)
425	Cardiomyopathy	(A 84)
426	Pulmonary heart disease	(A 84)
427	Symptomatic heart disease	(A 84)
428	Other myocardial insufficiency	(A 84)
429	Ill-defined heart disease	(A 84)

Cerebrovascular disease (430-438)

430	Subarachnoid haemorrhage	(A 85)
431	Cerebral haemorrhage	(A 85)
432	Occlusion of pre-cerebral arteries	(A 85)
433	Cerebral thrombosis	(A 85)
434	Cerebral embolism	(A 85)
435	Transient cerebral ischaemia	(A 85)
436	Acute but ill-defined cerebrovascular disease	(A 85)
437	Generalized ischaemic cerebrovascular disease	(A 85)
438	Other and ill-defined cerebrovascular disease	(A 85)

Disease of arteries, arterioles and capillaries (440-448)

440	Arteriosclerosis	(A 86)
441	Aortic aneurym (non-syphilitic)	(A 86)
442	Other aneurysm	(A 86)
443	Other peripheral vascular disease	(A 86)

444	Arterial embolism and thrombosis	(A 86)
445	Gangrene	(A 86)
446	Polyarteritis nodosa and allied conditions	(A 86)
447	Other diseases of arteries and arterioles	(A 86)
448	Diseases of capillaries	(A 86)

Diseases of veins and lymphatics, and other diseases of circulatory system (450-458)

450	Pulmonary embolism and infarction	(A 87)
451	Phlebitis and thrombophlebitis	(A 87)
452	Portal vein thrombosis	(A 87)
453	Other venous embolism and thrombosis	(A 87)
454	Varicose veins of lower extremities	(A 88)
455	Haemorrhoids	(A 88)
456	Varicose veins of other sites	(A 88)
457	Non-infective disease of lymphatic channels	(A 88)
458	Other diseases of circulatory system	(A 88)

VIII. DISEASES OF THE RESPIRATORY SYSTEM

Acute respiratory infections (except influenza) (460--466)

460	Acute nasopharyngitis (common cold)	(A 89)
461	Acute sinusitis	(A 89)
462	Acute pharyngitis	(A 89)
463	Acute tonsillitis	(A 89)
464	Acute laryngitis and tracheitis	(A 89)
465	Acute upper respiratory infection of multiple or unspecified sites	(A 89)
466	Acute bronchitis and bronchiolitis	(A 89)

Influenza (470-474)

470	Influenza unqualified	(A 90)
471	Influenza with pneumonia	(A 90)
472	Influenza with other respiratory manifestations	(A 90)
473	Influenza with digestive manifestations	(A 90)
474	Influenza with nervous manifestations	(A 90)

Pneumonia (480-486)

480	Viral pneumonia	(A 91)
481	Pneumococcal pneumonia	(A 92)
482	Other bacterial pneumonia	(A 92)
483	Pneumonia due to other specified organism	(A 92)
484	Acute interstitial pneumonia	(A 92)
485	Bronchopneumonia, unspecified	(A 92)
486	Pneumonia, unspecified,	(A 92)

Bronchitis, emphysema and asthma (490-493)

490	Bronchitis, unqualified	(A 93)
491	Chronic bronchitis	(A 93)
492	Emphysema	(A 93)
493	Asthma	(A 93)

Other diseases of upper respiratory tract (500-508)

500	Hypertrophy of tonsils and adenoids	(A 94)
501	Peritonsillar abscess	(A 96)
502	Chronic pharyngitis and nasopharyngitis	(A 96)
503	Chronic sinusitis	(A 96)
504	Deflected nasal septum	(A 96)
505	Nasal polyp	(A 96)
506	Chronic laryngitis	(A 96)
507	Hay fever	(A 96)
508	Other diseases of upper respiratory tract	(A 96)

Other diseases of respiratory system (510-519)

510	Empyema	(A 95)
511	Pleurisy	(A 96)
512	Spontaneous pneumothorax	(A 96)
513	Abscess of lung	(A 95)
514	Pulmonary congestion and hypostasis	(A 96)
515	Pneumoconiosis due to silica and silicates	(A 96)
516	Other pneumoconioses and related diseases	(A 96)
517	Other chronic interstitial pneumonia	(A 96)
518	Bronchiectasis	(A 96)
519	Other diseases of respiratory system	(A 96)

IX. DISEASES OF THE DIGESTIVE SYSTEM

Diseases of oral cavity, salivary glands and jaws (520-529)

520	Disorders of tooth development and eruption	(A 97)
521	Diseases of hard tissues of the teeth	(A 97)
522	Diseases of pulp and periapical tissues	(A 97)
523	Periodontal diseases	(A 97)
524	Other diseases and conditions including malocclusion	(A 97)
525	Other diseases and conditions of the teeth and supporting structures	(A 97)
526	Diseases of the jaws	(A 104)
527	Diseases of the salivary glands	(A 104)
528	Diseases of the oral soft tissues, excluding gingiva and tongue	(A 104)
529	Diseases of the tongue and other oral conditions	(A 104)

Diseases of oesophagus, stomach and duodenum (530-537)

530	Diseases of oesophagus	(A 104)
531	Ulcer of stomach	(A 98)
532	Ulcer of duodenum	(A 98)
533	Peptic ulcer, site unspecified	(A 98)
534	Gastrojejunal ulcer	(A 104)
535	Gastritis and duodenitis	(A 99)
536	Disorders of function of stomach	(A 104)
537	Other diseases of stomach and duodenum	(A 104)

Appendicitis (540-543)

540	Acute appendicitis	(A 100)
541	Appendicitis, unqualified	(A 100)
542	Other appendicitis	(A 100)
543	Other diseases of appendix	(A 100)

Hernia of abdominal cavity (550-553)

550	Inguinal hernia without mention of obstruction	(A 101)
551	Other hernia of obdominal cavity without mention of obstruction	(A 101)
552	Inguinal hernia with obstruction	(A 101)
553	Other hernia of abdominal cavity with obstruction	(A 101)

Other diseases of intestine and peritoneum (560--569)

560	Intestinal obstruction without mention of hernia	(A 101)
561	Gastro-enteritis and colitis, except ulcerative, of non-infectious origin	(A 104)
562	Diverticula of intestine	(A 104)
563	Chronic enteritis and ulcerative colitis	(A 104)
564	Functional disorders of intestines	(A 104)
565	Anal fissure and fistula	(A 104)
566	Abscess of anal and rectal regions	(A 104)
567	Peritonitis	(A 104)
568	Peritoneal adhesions	(A 104)
569	Other diseases of intestines and peritoneum	(A 104)

Diseases of liver, gallbladder and pancreas (570-577)

570	Ocute and subacute necrosis of liver	(A 104)
571	Cirrhosis of liver	(A 102)
572	Suppurative hepatitis and liver abscess	(A 104)
573	Other diseases of liver	(A 104)
574	Cholelithiasis	(A 103)
575	Cholecystitis and cholangitis, without mention of calculi	(A 103)
576	Other diseases of gallbladder and biliary ducts	(A 104)
577	Diseases of pancreas	(A 104)

X. DISEASES OF GENITO-URINARY SYSTEM

Nephritis and nephrosis (580-584)

580	Acute nephritis	(A 105)
581	Nephrotic syndrome	(A 106)
582	Chronic nephritis	(A 106)
583	Nephritis, unqualified	(A 106)
584	Renal sclerosis, unqualified	(A 106)

Other diseases of urinary system (590-599)

590	Infections of kidney	(A 107)
591	Hydronephrosis	(A 111)
592	Calculus of kidney and ureter	(A 108)
593	Other diseases of kidney and ureter	(A 111)
594	Calculus of other parts of urinary system	(A 108)
595	Cystitis	(A 111)
596	Other diseases of bladder	(A 111)
597	Urethritis (non-venereal)	(A 111)
598	Stricture of urethra	(A 111)
599	Other diseases of urinary tract	(A 111)

Diseases of male genital organs (600-607)

600	Hyperplasia of prostate	(A 109)
601	Prostatitis	(A 111)
602	Other diseases of prostate	(A 111)
603	Hydrocele	(A 111)
604	Orchitis and epididymitis	(A 111)
605	Redundant prepuce and phimosis	(A 111)
606	Sterility, male	(A 111)
607	Other diseases of male genital organs	(A 111)

Diseases of breast, ovary, fallopian tube and parametrium (610-616)

610	Chronic cystic disease of breast	(A 110)
611	Other diseases of breast	(A 110)
612	Acute salpingitis and oophoritis	(A 111)
613	Chronic Salpingitis and oophoritis	(A 111)
614	Salpingitis and oophoritis, unqualified	(A 111)
615	Other diseases of ovary and fallopian tube	(A 111)
616	Diseases of parametrium and pelvic peritoneum (female)	(A 111)

Diseases of uterus and other female genital organs (620-629)

620	Infective diseases of cervix uteri	(A 111)
621	Other diseases of cervix	(A 111)
622	Infective diseases of uterus (except cervix), vagina and vulva	(A 111)
623	Uterovaginal prolapse	(A 111)
624	Malposition of uterus	(A 111)
625	Other diseases of uterus	(A 111)
626	Disorders of menstruation	(A 111)
627	Menopausal symptoms	(A 111)
628	Sterility, female	(A 111)
629	Other diseases of female genital organs	(A 111)

XI. COMPLICATIONS OF PREGNANCY, CHILDBIRTH AND THE PUERPERIUM

Complications of pregnancy (630-634)

630	Infections of genital tract during pregnancy	(A 117)
631	Ectopic pregnancy	(A 117)
632	Haemorrhage of pregnancy	(A 113)
633	Anaemia of pregnancy	(A 117)
634	Other complications of pregnancy	(A 117)

Urinary infections and toxaemias of pregnancy and the puerperium (635-639)

635	Urinary infections arising during pregnancy and the puerperium	(A 112)
636	Renal disease arising during pregnancy and the puerperium	(A 112)
637	Pre-eclampsia, eclampsia and toxaemia, unspecified	(A 112)
638	Hyperemesis gravidarum	(A 112)
639	Other toxaemias of pregnancy and the puerperium	(A 112)

Abortion (640-645)

640	Abortion induced for medical indications	(A 114)
641	Abortion induced for other legal indications	(A 114)
642	Abortion induced for other reasons	(A 115)
643	Spontaneous abortion	(A 115)
644	Abortion not specified as induced or spontaneous	(A 115)
645	Other abortion	(A 115)

Delivery (650-662)

650	Delivery without mention of complication	(A 118)
651	Delivery complicated by placenta praevia or antepartum haemorrhage	(A 113)
652	Delivery complicated by retained placenta	(A 113)
653	Delivery complicated by other postpartum haemorrhage	(A 113)
654	Delivery complicated by abnormality of bony pelvis	(A 117)
655	Delivery complicated by foetopelvic disproportion	(A 117)

656	Delivery complicated by malpresentation of foetus	(A 117)
657	Delivery complicated by prolonged labour of other origin	(A 117)
658	Delivery with laceration of perineum, without mention of other laceration	(A 117)
659	Delivery with rupture of uterus	(A 117)
660	Delivery with other obstetrical trauma	(A 117)
661	Delivery with other complications	(A 117)
662	Anaesthetic death in uncomplicated delivery	(A 117)

Complications of the puerperium (670-678)

670	Sepsis of childbirth and the puerperium	(A 116)
671	Puerperal phlebitis and thrombosis	(A 116)
672	Pyrexia of unknown origin during the puerperium	(A 117)
673	Puerperal pulmonary embolism	(A 116)
674	Cerebral haemorrhage in the puerperium	(A 117)
675	puerperal blood dyscrasias	(A 117)
676	Anaemia of puerperium	(A 117)
677	Other and unspecified complications of the puerperium	(A 117)
678	Mastitis and other disorders of lactation	(A 117)

XII. DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE

Infections of skin and subcutaneous tissue (680-686)

680	Boil and carbuncle	(A 119)
681	Cellulitis of finger and toe	(A 119)
682	Other cellulitis and abscess	(A 119)
683	Acute lymphadenitis	(A 119)
684	Impetigo	(A 119)
685	Pilonidal cyst	(A 119)
686	Other local infections of skin and subcutaneous tissue	(A 119)

Other inflammatory conditions of skin and subcutaneous tissue (690-698)

690	Seborrhoeic dermatitis	(A 120)
691	Infantile eczema and related conditions	(A 120)
692	Other eczema and dermatitis	(A 120)
693	Dermatitis herpetiformis	(A 120)
694	Pemphigus	(A 120)
695	Erythematous conditions	(A 120)
696	Psoriasis and similar disorders	(A 120)
697	Lichen	(A 120)
698	Pruritus and related conditions	(A 120)

Other diseases of skin and subcutaneous tissue (700-709)

700	Corns and callosities	(A 120)
701	Other hypertrophic and atrophic conditions of skin	(A 120)
702	Other dermatoses	(A 120)
703	Diseases of nail	(A 120)
704	Diseases of hair and hair follicles	(A 120)
705	Diseases of sweat glands	(A 120)
706	Diseases of sebaceous glands	(A 120)
707	Chronic ulcer of skin	(A 120)
708	Urticaria	(A 120)
709	Other diseases of skin	(A 120)

XIII. DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE

Arthritis and rheumatism, except rheumatic fever (710-718)

710	Acute arthritis due to pyogenic organisms	(A 121)
711	Acute non-pyogenic arthritis	(A 121)
712	Rheumatoid arthritis and allied conditions	(A 121)
713	Osteo-arthritis and allied conditions	(A 121)
714	Other specified forms of arthritis	(A 121)
715	Arthritis, unspecified	(A 121)
716	Polymyositis and dermatomyositis	(A 122)
717	Other non-articular rheumatism	(A 122)
718	Rheumatism, unspecified	(A 122)

Osteomyelitis and other diseases of bone and joint (720-729)

720	Osteomyelitis and periostitis	(A 123)
721	Osteitis deformans	(A 125)
722	Osteochondrosis	(A 125)
723	Other diseases of bone	(A 125)
724	Internal derangement of joint	(A 125)
725	Displacement of intervertebral disc	(A 125)
726	Affection of sacro-iliac joint	(A 125)
727	Ankylosis of joint	(A 124)
728	Vertebrogenic pain syndromes	(A 125)
729	Other diseases of joint	(A 125)

Other diseases of musculoskeletal system (730-738)

730	Bunion	(A 125)
731	Synovitis, bursitis and tenosynovitis	(A 125)
732	Infective myositis and other inflammatory diseases of tendon and fascia	(A 125)
733	Other diseases of muscle, tendon and fascia	(A 125)
734	Diffuse diseases of connective tissue	(A 125)
735	Curvature of spine	(A 124)
736	Flat foot	(A 124)
737	Hallux valgus and varus	(A 124)
738	Other deformities	(A 124)

XIV. CONGENITAL ANOMALIES

740	Anencephalus	(A 130)
741	Spina bifida	(A 126)
742	Congenital hydrocephalus	(A 130)
743	Other congenital anomalies of nervous system	(A 130)
744	Congenital anomalies of eye	(A 130)
745	Congenital anomalies of ear, face and neck	(A 130)
746	Congenital anomalies of heart	(A 127)
747	Other congenital anomalies of circulatory system	(A 128)
748	Congenital anomalies of respiratory system	(A 130)
749	Cleft palate and cleft lip	(A 129)
750	Other congenital anomalies of upper alimentary tract	(A 130)
751	Other congenital anomalies of digestive system	(A 130)
752	Congenital anomalies of genital organs	(A 130)
753	Congenital anomalies of urinary system	(A 130)
754	Clubfoot (congenital)	(A 130)
755	Other congenital anomalies of limbs	(A 130)

756	Other congenital anomalies of musculoskeletal system	(A 130)
757	Congenital anomalies of skin, hair and nails	(A 130)
758	Other and unspecified congenital anomalies	(A 130)
759	Congenital syndromes affecting multiple system	(A 130)

XV. CERTAIN CAUSES OF PERINATAL MORBIDITY AND MORTALITY

760	Chronic circulatory and genitourinary disease in mother	(A 135)
761	Other maternal conditions unrelated to pregnancy	(A 135)
762	Toxaemia of pregnancy	(A 135)
763	Maternal ante and intrapartum infection	(A 135)
764	Difficult labour with abnormality of bones, organs or tissues of pelvis	(A 131)
765	Difficult labour with disproportion but no mention of abnormality of pelvis	(A 131)
766	Difficult labour with malposition of foetus	(A 131)
767	Difficult labour with abnormality of forces of labour	(A 131)
768	Difficult labour with other and unspecified complications	(A 131)
769	Other complications of pregnancy and childbirth	(A 135)
770	Conditions of placenta	(A 132)
771	Conditions of umbilical cord	(A 132)
772	Birth injury without mention of cause	(A 131)
773	Termination of pregnancy	(A 135)
774	Haemolytic disease of newborn with kernicterus	(A 133)
775	Haemolytic disease of newborn without mention of kernicterus	(A 133)
776	Anoxic and hypoxic conditions not elsewhere classified	(A 134)
777	Immaturity, unqualified	(A 135)
778	Other conditions of foetus or newborn	(A 135)
779	Foetal death of unknown cause	(A 135)

XVI. SYMPTOMS AND ILLDEFINED CONDITIONS

Symptoms referable to systems or organs (780-789)

780	Certain symptoms referable to nervous system and special senses	(A 137)
781	Other symptoms referable to nervous system and special senses	(A 137)
782	Symptoms referable to cardiovascular and lymphatic system	(A 137)
783	Symptoms referable to respiratory system	(A 137)
784	Symptoms referable to upper gastro-intestinal tract	(A 137)
785	Symptoms referable to abdomen and lower gastro-intestinal tract	(A 137)
786	Symptoms referable to genito urinary system	(A 137)
787	Symptoms referable to limbs and joints	(A 137)
788	Abnormal urinary constituents of unspecified cause	(A 137)

Senility and ill-defined diseases (790-796)

790	Nervousness and debility	(A 137)
791	Headache	(A 137)
792	Uraemia	(A 137)
793	Observation, without need for further medical care	(A 137)
794	Senility without mention of psychosis	(A 136)
795	Sudden death (cause unknown)	(A 137)
796	Other ill-defined and unknown cause of morbidity and mortality	(A 137)

N XVII. ACCIDENTS, POISONINGS AND VIOLENCE (NATURE OF INJURY)

Fracture of skull, spine, and trunk (N800-N809)

N800	Fracture of vault of skull	(AN 138)
N801	Fracture of base of skull	(AN 138)
N802	Fracture of face bones	(AN 138)
N803	Other and unqualified skull fractures	(AN 138)
N804	Multiple fractures involving skull or face with other bones	(AN 138)
N805	Fracture and fracture dislocation of vertebral column without mention of spinal cord lesion	(AN 139)
N806	Fracture and fracture dislocation of vertebral column with spinal cord lesion	(AN 139)
N807	Fracture of rib(s), sternum and larynx	(AN 139)
N808	Fracture of pelvis	(AN 139)
N809	Multiple and ill-defined fractures of trunk	(AN 139)

Fracture of upper limb (N810-N819)

N810	Fracture of clavicle	(AN 140)
N811	Fracture of scapula	(AN 140)
N812	Fracture of humerus	(AN 140)
N813	Fracture of radius and ulna	(AN 140)
N814	Fracture of carpal bone(s)	(AN 140)
N815	Fracture of metacarpal bone(s)	(AN 140)
N816	Fracture of one or more phalanges of hand	(AN 140)
N817	Multiple fractures of hand bones	(AN 140)
N818	Other, multiple, and ill-defined fractures of upper limb	(AN 140)
N819	Multiple fractures both upper limbs, and upper limb with rib(s) and sternum	(AN 140)

Fracture of lower limb (N820-N829)

N820	Fracture of neck of femur	(AN 140)
N821	Fracture of other and unspecified parts of femur	(AN 140)
N822	Fracture of patella	(AN 140)
N823	Fracture of tibia and fibula	(AN 140)
N824	Fracture of ankle	(AN 140)
N825	Fracture of one or more tarsal and metatarsal bones	(AN 140)
N826	Fracture of one or more phalanges of foot	(AN 140)
N827	Other, multiple, and ill-defined fractures of lower limb	(AN 140)
N828	Multiple fractures involving both lower limbs, lower with upper limb, and lower limb(s) with rib(s) and sternum	(AN 140)
N829	Fracture of unspecified bones	(AN 140)

Dislocation without fracture (N830-N839)

N830	Dislocation of jaw	(AN 141)
N831	Dislocation of shoulder	(AN 141)
N832	Dislocation of elbow	(AN 141)
N833	Dislocation of wrist	(AN 141)
N834	Dislocation of finger	(AN 141)
N835	Dislocation of hip	(AN 141)
N836	Dislocation of knee	(AN 141)
N837	Dislocation of ankle	(AN 141)
N838	Dislocation of foot	(AN 141)
N839	Other multiple and ill-defined dislocations	(AN 141)

Sprains and strains of joints and adjacent muscles (N840-N848)

N840	Sprains and strains of shoulder and upper arm	(AN 142)
N841	Sprains and strains of elbow and forearm	(AN 142)
N842	Sprains and strains of wrist and hand	(AN 142)
N843	Sprains and strains of hip and thigh	(AN 142)
N844	Sprains and strains of knee and leg	(AN 142)
N845	Sprains and strains of ankle and foot	(AN 142)
N846	Sprains and strains of sacro-iliac region	(AN 142)
N847	Sprains and strains of other and unspecified parts of back	(AN 142)
N848	Other and ill-defined sprains and strains	(AN 142)

Intracranial injury (excluding those with skull fracture) (N850-N854)

N850	Concussion	(AN 143)
N851	Cerebral laceration and contusion	(AN 143)
N852	Subarachnoid, subdural and extradural haemorrhage, following injury (without mention of cerebral laceration or contusion)	(AN 143)
N853	Other and unspecified intracranial haemorrhage following injury (without mention of cerebral laceration or contusion)	(AN 143)
N854	Intracranial injury of other and unspecified nature	(AN 143)

Internal injury of chest, abdomen and pelvis (N860-N869)

N860	Traumatic pneumothorax and haemothorax	(AN 144)
N861	Injury to heart and lung	(AN 144)
N862	Injury to other and unspecified intrathoracic organs	(AN 144)
N863	Injury to gastro-intestinal tract	(AN 144)
N864	Injury to liver	(AN 144)
N865	Injury to spleen	(AN 144)
N866	Injury to kidney	(AN 144)
N867	Injury to pelvic organs	(AN 144)
N868	Injury to other and unspecified intra-abdominal organs	(AN 144)
N869	Internal injury, unspecified or involving intrathoracic and intra-abdominal organs	(AN 144)

Laceration and open wound of head neck and trunk (N870-N879)

N870	Open wound of eye and orbit	(AN 145)
N871	Enucleation of eye	(AN 145)
N872	Open wound of ear	(AN 145)
N873	Other and unspecified laceration of head	(AN 145)
N874	Open wound of neck	(AN 145)
N875	Open wound of chest (wall)	(AN 145)
N876	Open wound of back	(AN 145)
N877	Open wound of buttock	(AN 145)
N878	Open wound of genital organs (external), including traumatic amputation	(AN 145)
N879	Other, multiple and unspecified open wounds of head, neck and trunk	(AN 145)

Laceration and open wound of upper limb (N880-N887)

N880	Open wound of shoulder and upper arm	(AN 145)
N881	Open wound of elbow, forearm and wrist	(AN 145)
N882	Open wound of hand, except finger(s) alone	(AN 145)
N883	Open wound of finger (s)	(AN 145)
N884	Multiple and unspecified open wound of upper limb	(AN 145)
N885	Traumatic amputation of thumb (complete) (partial)	(AN 145)
N886	Traumatic amputation of other finger(s) (complete) (partial)	(AN 145)
N887	Traumatic amputation of arm and hand (complete) (partial)	(AN 145)

Laceration and open wound of lower limb (N890-N897)

N890	Open wound of hip and thigh	(AN 145)
N891	Open wound of knee, leg (except thigh), and ankle	(AN 145)
N892	Open wound of foot, except toe(s) alone	(AN 145)
N893	Open wound of toe(s)	(AN 145)
N894	Multiple and unspecified open wound of lower limb	(AN 145)
N895	Traumatic amputation of toe(s) (complete) (partial)	(AN 145)
N896	Traumatic amputation of foot (complete) (partial)	(AN 145)
N897	Traumatic amputation of leg(s) (complete) (partial)	(AN 145)

Laceration and open wound of multiple location (N900-N907)

N900	Multiple open wounds of both upper limbs	(AN 145)
N901	Multiple open wounds of both lower limbs	(AN 145)
N902	Multiple open wounds of upper with lower limb(s)	(AN 145)
N903	Multiple open wounds of both hands	(AN 145)
N904	Multiple open wounds of head with limb(s)	(AN 145)
N905	Multiple open wounds of trunk with limb(s)	(AN 145)
N906	Multiple open wounds of face with limb(s)	(AN 145)

N907	Multiple open wounds of other and unspecified location	(AN 145)

Superficial injury (N910-N918)

N910	Superficial injury of face, neck, scalp	(AN 146)
N911	Superficial injury of trunk	(AN 146)
N912	Superficial injury of shoulder and upper arm	(AN 146)
N913	Superficial injury of elbow, forearm and wrist	(AN 146)
N914	Superficial injury of hands(s) except finger(s) alone	(AN 146)
N915	Superficial injury of finger(s)	(AN 146)
N916	Superficial injury of hip, thigh, leg and ankle	(AN 146)
N917	Superficial injury of foot and toe(s)	(AN 146)
N918	Superficial injury of other, multiple and unspecified sites	(AN 146)

Contusion and crushing with intact skin surface (N920-N929)

N920	Contusion of face, scalp and neck except eye(s)	(AN 146)
N921	Contusion of eye and orbit	(AN 146)
N922	Contusion of trunk	(AN 146)
N923	Contusion of shoulder and upper arm	(AN 146)
N924	Contusion of elbow, forearm and wrist	(AN 146)
N925	Contusion of hand(s) except finger(s) alone	(AN 146)
N926	Contusion of finger(s)	(AN 146)
N927	Contusion of hip, thigh, leg and ankle	(AN 146)
N928	Contusion of foot and toe(s)	(AN 146)
N929	Contusion of other, multiple and unspecified sites	(AN 146)

Effects of foreign body entering through orifice (N930-N939)

N930	Foreign body in eye and adnexa	(AN 147)
N931	Foreign body in ear	(AN 147)
N932	Foreign body in nose	(AN 147)
N933	Foreign body in pharynax and larynx	(AN 147)
N934	Foreign body in bronchus and lung	(AN 147)
N935	Foreign body in mouth, oesophagus, and stomach	(AN 147)
N936	Foreign body in intestine and colon	(AN 147)
N937	Foreign body in anus and rectum	(AN 147)
N938	Foreign body in digestive system unspecified	(AN 147)
N939	Foreign body in genitourinary tract	(AN 147)

Burn (N940-N949)

N940	Burn confined to eye	((AN 148)
N941	Burn confined to face, head and neck	(AN 148)
N942	Burn confined to trunk	(AN 148)
N943	Burn confined to upper limb, except wrist and hand	(AN 148)
N944	Burn confined to writ(s) and hand(s)	(AN 148)
N945	Burn confined to lower limb(s)	(AN 148)
N946	Burn involving face, head and neck with limb(s)	(AN 148)
N947	Burn involving trunk with limb(s)	(AN 148)
N948	Burn involving face, head and neck with trunk and limb(s)	(AN 148)
N949	Burn involving other and unspecified parts	(AN 148)

Injury to nerves and spinal cord (N950-N959)

N950	Injury to optic nerve(s)	(AN 150)
N951	Injury to other cranial nerve(s)	(AN 150)
N952	Injury to nerve(s) in upper arm	(AN 150)
N953	Injury to nerve(s) in forearm	(AN 150)
N954	Injury to nerve(s) in wrist and hand	(AN 150)
N955	Injury to nerve(s) in thigh	(AN 150)
N956	Injury to nerve(s) in lower leg	(AN 150)
N957	Injury to nerve(s) in ankle and foot	(AN 150)
N958	Spinal cord lesion without evidence of spinal bone injury	(AN 150)
N959	Other nerve injury including nerve injury in several parts	(AN 150)

Adverse effect of medicinal agents (N960-N979)

N960	Adverse effect of antibiotics	(AN 149)
N961	Adverse effect of other anti-infectives	(AN 149)
N962	Adverse effect of hormones and synthetic substitutes	(AN 149)
N963	Adverse effect of primarily systemic agents	(AN 149)
N964	Adverse effect of agents primarily affecting blood constituents	(AN 149)
N965	Adverse effect of analgesics and antipyretics	(AN 149)
N966	Adverse effect of anticonvulsants	(AN 149)
N967	Adverse effect of other sedatives and hypnotics	(AN 149)
N968	Adverse effect of other central nervous system depressants	(AN 149)
N969	Adverse effect of local anaesthetic	(AN 149)
N970	Adverse effect of psychotherapeutics	(AN 149)
N971	Adverse effect of other central nervous system stimulants	(AN 149)
N972	Adverse effect of agents primarily affecting the autonomic nervous system	(AN 149)
N973	Adverse effect of agents primarily affecting cardiovascular system	(AN 149)
N974	Adverse effect of drugs primarily effecting gastrointestinal system	(AN 149)
N975	Adverse effect of diuretics	(AN 149)
N976	Adverse effect of agents acting directly upon musculoskeletal system	(AN 149)
N977	Adverse effect of other and unspecified drugs	(AN 149)
N978	Adverse effect of two or more medicinal agents in specified combinations	(AN 149)
N979	Alcohol in combination with specified medicinal agents	(AN 149)

Toxic effect of substances chiefly non-medicinal as to source (N980-N989)

N980	Toxic effect of alcohol	(AN 149)
N981	Toxic effect of petroleum products	(AN 149)
N982	Toxic effect of industrial solvents	(AN 149)
N983	Toxic effect of corrosive aromatics, acids and caustic alkalis	(AN 149)
N984	Toxic effect of lead and its compounds (including fumes)	(AN 149)
N985	Toxic effect of other metals chiefly non-medicinal as to source	(AN 149)
N986	Toxic effect of carbon monoxide	(AN 149)
N987	Toxic effect of other gases, fumes or vapours	(AN 149)
N988	Toxic effect of noxious foodstuffs	(AN 149)
N989	Toxic effect of other substances chiefly non-medicinal as to source	(AN 149)

Other adverse effects (N990-N999)

N990	Effects of radiation	(AN 150)
N991	Effects of reduced temperature	(AN 150)
N992	Effects of heat	(AN 150)
N993	Effects of air pressure	(AN 150)
N994	Effects of other external causes	(AN 150)
N995	Certain early complications of trauma	(AN 150)
N996	Inury, other and unspecified	(AN 150)
N997	Complications peculiar to certain surgical procedures	(AN 150)
N998	Other complications of surgical procedures	(AN 150)
N999	Other complications of medical care	(AN 150)

Notification

ILD/HS/2266/65-II

Govt. of India, Ministry of Petroleum and Chemicals and Mines and Metals (Department of Petroleum and Chemicals), New Delhi, Orders No. 17(7)/ /70-Ch. III dated 16th May 1970 and 18th May 1970, published in Govt. of India Gazette Extraordinary, Part II Section 3 Sub-section (ii), is hereby re-published for general public information.

By order and in the name of the Administrator of Goa, Daman and Diu.

D. N. Barua, Secretary, Public Health Dept.

Panaji, 22nd January, 1971.

GOVERNMENT OF INDIA

MINISTRY OF PETROLEUM & CHEMICALS AND MINES & METALS

(Department of Petroleum and Chemicals)

Order

New Delhi the 16th May 1970

S. O. 1752. — In exercise of the powers conferred by section 3 of the Essential Commodities Act, 1955 (10 of 1955) and in supersession of the Drugs Prices (Display and Control) Order, 1966, the Central Government hereby makes the following Order, namely: —

1. Short title, extent and commencement. — (1) This Order may be called the Drugs (Prices Control) Order, 1970.

(2) It extends to the whole of India.

(3) It shall come into force on the date of its publication in the Official Gazette.

2. Definitions. — In this Order, unless the context otherwise requires,—

(a) "bulk drug" means any un-processed pharmaceutical chemical conforming to pharmacopoeial or other accepted standards which is used for being processed into formulations and includes an essential bulk drug;

(b) "dealer" means a person carrying on the business of purchase or sale of drugs, whether wholesale or retail and whether or not in conjunction with any other business and includes a retailer and an agent of a dealer;

(c) "distributor" means a distributor of drugs or his agent or a stockist appointed by the manufacturer or importer for stocking his drugs for resale to a dealer;

(d) "drug" includes a bulk drug and a formulation as defined in this Order;

(e) "essential bulk drug" means a bulk drug specified in Schedule I;

(f) "Form" means a Form specified in Schedule II;

(g) "formulation" means a medicine processed out of one or more bulk drugs with or without the use of any pharmaceutical aids for internal or external use in the diagnosis, treatment, mitigation or prevention of disease in human beings or animals, but shall not include —

(i) any medicine mentioned in, and processed and manufactured exclusively in accordance with the formulae described in, the authoritative books of Ayurvedic (including Siddha) and Unani (Tibb) systems of medicine, specified in the First Schedule to the Drugs and Cosmetics Act, 1940 (23 of 1940);

(ii) any medicine included in the Homoeopathic system of medicine;

(iii) coal-tar disinfectant fluids;

(iv) the following insecticides, namely:

(a) Benzene Hexachloride and its preparations;

(b) Di-chloro Diphenol-Trichloro Ethane and its preparations;

(c) Dieldrin and its preparations;

(d) Pyrethrum and its preparations;

(v) such substances intended to affect the structure or any function of the human body as may, from time to time, be specified by the Central Government, by notification in the Official Gazette;

(h) "import" with its grammatical variations and cognate expressions, means bringing into India from a place outside India; and "importer" in relation to any goods at any time between their importation and the time when they are cleared for home con-

sumption, includes any owner or any person holding himself out to be the importer;

(i) "intermediary" means any person by whatsoever name called who is engaged in the distribution or sale of a drug between the manufacturer and the retailer and includes a distributor or a wholesaler of drugs;

(j) "manufacture" in relation to any drug includes any process or part of a process for making, altering, finishing, packing, labelling, breaking-up or otherwise treating or adapting any drug with a view to its sale and distribution, but does not include the compounding or dispensing of any drug or the packing of any drug in the ordinary course of retail business, and "to manufacture" shall be construed accordingly;

(k) "manufacturer" means any person who manufactures a drug;

(l) "manufacturer's price" means the price calculated in accordance with the provisions of this Order at which a drug shall be sold by a manufacturer or importer or distributor to an intermediary;

(m) "price list" means the price list referred to in paragraph 8;

(n) "retail price" means the retail price of a formulation calculated in accordance with the provisions of this Order;

(o) "retailer" means a dealer carrying on the business of sale of drugs to customers;

(p) "Schedule" means a Schedule appended to this Order;

3. **Power to amend Schedule I.** — The Central Government may, having regard to the importance or otherwise of any bulk drug for the health and well-being of the community, add to, or omit the said bulk drug from, Schedule I.

4. **Power to fix the maximum sale price of an essential bulk drug.** — (1) The Central Government may, with a view to regulating equitable distribution of an essential bulk drug and making the same available at a fair price, from time to time fix, by notification in the Official Gazette, the maximum price at which the said essential bulk drug shall be sold:

Provided that before fixing the maximum price in respect of an essential bulk drug, it shall be the duty of the Central Government to institute such inquiry as it deems fit for the purpose:

Provided further that, as regards the fixation of the maximum price of the essential bulk drugs included in Schedule I at the commencement of this Order, the recommendations made in this behalf by the Tariff Commission in its Report of August, 1968 shall form the basis and no such inquiry as aforesaid shall be necessary.

(2) No person shall sell an essential bulk drug at a price exceeding the price fixed for the same under this paragraph plus local taxes payable if any.

5. **Maximum selling prices of bulk drugs.** — (1) Every manufacturer, importer or distributor of a bulk drug, shall report to the Central Government within two weeks of the commencement of the Order, the name of the bulk drug marketed by him or used exclusively by him for formulations, and its maximum selling price or the notional price as the case may be, at the time of the commencement of this Order, and he shall not thereafter increase the said selling price or notional price of such bulk drug without the prior approval of the Central Government for which purpose he shall also furnish information as required in Form No. 1.

(2) The provisions of sub-paragraph (1) shall apply also to bulk drugs introduced after the commencement of this Order except that the said period of two weeks shall be computed from the date of introduction of the said bulk drug.

(3) No person shall sell a bulk drug at a price exceeding the price referred to in sub-paragraph (1) plus local taxes payable if any.

6. **Calculation of retail prices of formulations.** — The retail price of a formulation shall be calculated in accordance with the following formula, namely: —

$$R.P. = (M.C.+C.C.+P.C.) \times \frac{(1+MU)}{100)} + E.D.$$

where R.P. means retail price;

MC. means material cost and includes the cost of drugs and pharmaceutical aids used;

C.C. means the conversion cost worked out in accordance with such norms as may be specified by the Central Government from time to time by notification in the Official Gazette in this behalf;

P.C. means packing charges and includes the cost of packing materials and packaging expenses worked out in accordance with such norms as may be specified by the Central Government from time to time by notification in the Official Gazette in this behalf;

M.U. means mark-up referred to in paragraph 7;

E.D. means excise duty:

Provided that in the case of an importer of a formulation, MC+CC+PC shall not be more than the landed cost of the formulation, and in the case re-packing, the actual cost of such re-packing subject to such ceiling as may be specified in the aforesaid norms.

Explanation: — Landed cost for the purposes of this paragraph means the cost of import inclusive of customs duty and clearing charges.

7. **Mark-Up.** — (M.U.) referred to in paragraph 6 shall be the following, namely: —

(i) 75 in the case of all formulations introduced before or after the commencement of this Order; but not falling in the category of —

(a) new formulations evolved by adoption of manufacturing techniques as a result of appreciable product development work which has improved their therapeutic value;

(b) new formulations containing as the active ingredient a new drug which is a product of original research in India;

(ii) 100 in the case of new formulations evolved by adoption of manufacturing techniques as a result of appreciable product deve-

lopment work which has improved their therapeutic value;

(iii) 150 in the case of new formulations containing as the active ingredient a new drug which is a product of original research in India.

Provided that in regard to formulations falling under clause (ii) above, the mark-up shall be reduced to 75 after a period of 3 years commencing from the date of introduction of the new formulation which in special cases, for reasons to be recorded in writing, may be extended by the Central Government to 5 years from the date of introduction of the said new formulation:

Provided further that in the case of formulations falling under clause (iii) above, the mark-up shall be reduced to 75 after a period of five years commencing from the date of introduction of the new formulation.

Explanation. — A mere change in dosage or formulation in the preparation of a formulation shall not be deemed to constitute a new formulation involving an appreciable product development work.

8. **Furnishing of price list by manufacturer, importer or distributor to dealer.** — Every manufacturer, importer or distributor of a formulation intended for sale shall furnish to the dealers a price list showing the manufacturer's price and the retail price of such formulation and the first such list shall be furnished to the dealers as required in Form No. 2, not later than two months from the commencement of this Order:

Provided that in cases where the Central Government is satisfied that the said period of two months is inadequate, having regard to the number of formulations marketed by a particular manufacturer, importer or distributor, the period may be extended to four months in the aggregate, in respect of all or some of the formulations except the formulations based on essential bulk drugs:

Provided further that when once a manufacturer, importer or distributor furnishes a price list to the dealer showing, the manufacturer's price and the retail price of the formulations marketed by him, it shall not be obligatory for such manufacturer or importer or distributor to furnish a fresh price list at the time of every subsequent sale to the dealer unless there is any change or addition in that list in which case a supplementary price list, including the changes or additions shall be furnished.

9. **Fixation of retail prices.** — (1) In making the price lists every manufacturer, importer or distributor shall calculate the retail price of a formulation marketed by him in accordance with the provisions of paragrapahs 6 and 7 and shall submit to the Central Government the price list accompanied by information and details of calculations regarding retail price as required in Form No. 3.

(2) The price list, accompanied by the information and details of the calculations referred to in sub-paragraph (1), shall be submitted to the Central Government within one week of its furnishing to the dealer.

10. **Special provisions in respect of formulations intended to be introduced after the commencement of this Order.** — Where a formulation is sought to be introduced after the commencement of this Order, every manufacturer or importer, as the case may be, of such formulation shall —

(a) intimate to the Central Government of the date on which such formulation is sought to be introduced either by way of manufacture or import and within a period of two months from that date he shall furnish to the dealers the price list referred to in paragraph 8;

(b) submit to the Central Government the said price list, together with the information and details of calculations referred to in sub-paragraph (1) of paragraph 9, within one week of his furnishing the said price list to the dealers.

11. **Power of the Central Government to scrutinise the price list and to fix the retail price in certain cases.** — (1) If on the scrutiny of the price list and the information and details of calculations furnished to it under paragraph 9, the Central Government is of opinion that the retail price of any formulation has not been correctly fixed in accordance with paragraph 6 or 7, it may fix the retail price of such formulation in accordance with the provisions of the said paragraphs and communicate the retail price so fixed to the manufacturer, importer or distributor, who shall forthwith amend the relevant price list and communicate the same to the dealers.

(2) The retail price of any formulation fixed by the Central Government under sub-paragraph (1) and the said amended price list shall come into force not later than fifteen days from the receipt of the aforesaid communication by the manufacturer, importer or distributor.

(3) The power under sub-paragraph (1) to fix the prices of formulations shall be exercised by the Central Government within four months from the date of receipt by it of the intimation of retail price for any formulation together with the information and details of calculations referred to in paragraph 9:

Provided that the said period of four months may be extended by the Central Government to six months in the case of formulations involving detailed examination:

Provided however, that an intimation that the period has been extended to six months shall be sent by the Central Government before the expiry of the said period of four months to the manufacturer, importer or distributor concerned.

12. **Determination of a new formulation.** — (1) The manufacturer, importer or distributor of a new formulation may, before introducing such a new formulation for sale or including the retail price of such a new formulation in the price list, apply to the Central Government for a decision as to whether the formulation constitutes a new formulation within the meaning of clause (i) (a) or clause (i) (b) of paragraph 7.

(2) Where an application is received under sub-paragraph (1), the Central Government may within a period of forty-five days of the receipt of the said application, by order, inform the applicant of its decision as to whether or not the formulation constitutes a new formulation as aforesaid.

(3) The manufacurer of such a new formulation may —

(i) on receipt of the order of the Central Government that the formulation constitutes a new formulation, or

(ii) where no such order is sent by the Central Government, before the expiry of the period of forty-five days referred to in sub-paragraph (2), follow the procedure laid down in paragraph 9 or 10, as the case may be, for introducing the new formulation for sale or including the retail price of such new formulation in the price list and the provisions of paragraph 7 shall in so far as they relate to the fixation of retail price apply to the said new formulation.

13. **Revision of prices.** — (1) The retail price of a formulation once fixed and brought into force in accordance with the provisions of this Order shall not be revised before the expiry of one year from the date the said retail price was brought into force.

(2) Subject to the provisions of sub-paragraph (1), —

(a) any manufacturer, importer or distributor, may, if he considers it necessary so to do, revise the retail price of any formulation marketed by him, in accordance with the provisions of paragraph 6 and 7 and thereupon the provisions of paragraphs 8 and 9 shall apply in the case of that formulation;

(b) it shall be lawful for the Central Government to revise the retail price of any formulation.

(3) For the purpose of such revision, the Central Government may call for such information regarding cost structure of any formulation as it may consider necessary from any manufacturer, importer or distributor and fix the retail price in accordance with paragraphs 6 and 7 in which case the manufacturer, importer or distributor, shall within fifteen days from the date of receipt of the Central Government's communication fixing the retail price of such formulation amend the price list and market the said formulation at the retail price fixed by the Central Government:

Provided that if the manufacturer, importer or distributor fails to furnish the required information within the time stipulated, the Central Government may on the basis of such information as is available with it, fix the retail price of the said formulation and communicate the same to the manufacturer, importer or distributor, and the manufacturer, importer or distributor shall within 15 days of the receipt of the aforesaid communication revise the price list accordingly, and market the formulation at the retail price so fixed.

14. **Alternative scheme of pricing.** — (1) Notwithstanding anything contained in the other provisions of this Order, the manufacturer, importer or distributor may, if he so chooses, submit to the Central Government for approval a scheme of prices covering all of the formulations marketed by him so that the overall gross profit before tax does not exceed 15 per cent of the sales turn-over as estimated by him and submit the price list resulting therefrom, alongwith such other information as is required in Schedule III, for the purpose, in which case the price list resulting therefrom as approved by the Central Government shall be the valid price list for the formulations marketed by the manufacturer, importer or distributor:

Provided that the scheme shall be subject to the following conditions, namely: —

(1) the formulations based on the essential bulk drugs shall be priced in accordance with the provisions of paragraphs 6 and 7;

(2) the formulations, based on the bulk drugs other than the essential bulk drugs shall be priced in such a way that under the prescribed formula the mark-up in any individual case does not exceed 150;

(3) the manufacturer, importer or distributor shall, on choosing the scheme, undertake and maintain separate accounts for formulations based on essential bulk drugs and the formulations based on other bulk drugs, and submit them for scrutiny in such manner as may be specified by the Central Government;

(4) in case the actual gross profit before tax for any particular year as shown in the audited accounts of the manufacturer, importer or distributor exceeds 15 per cent of the sales turn-over of that year, as certified by the auditor, the excess shall be funded separately and shall not be utilised for distribution of dividends but shall be utilised, with the prior approval of the Central Government, for any of the following purposes, namely: —

(i) research and development expenditure;

(ii) adjustment against future profits;

(iii) such other purposes as may be specified by the Central Government from time to time.

(2) The option referred to in sub-paragraph (1) shall be exercised and the price lists under the alternative pricing scheme shall be submitted by the manufacturer, importer or distributor, as the case may be, within two months of the commencement of this Order for the approval of the Central Government.

Provided further that in the case of a manufacturer, importer or distributor, facturer, importer or distributor may market his formulations as per price lists so submitted:

Provided further that in the case of a manufacturer, importer or distributor who markets his products for the first time, the aforesaid period of two months shall be computed from the date he commences production.

(3) If any difficulty arises in giving effect to the provisions of this paragraph, the Central Government may, from time to time, issue such orders, directions or instructions, not inconsistent with the provisions of this Order, as appear to it to be necessary or expedient for the removal of such difficulty.

15. **Control of sale prices of formulations.** — (1) No manufacturer, importer or distributor, shall sell any formulation to an intermediary at a price exceeding the manufacturer's price as shown in the price list plus the local taxes payable if any.

(2) No dealer shall sell any formulation to a customer at a price exceeding the retail price of that formulation shown in the price list plus the local taxes payable if any.

16. **Retail price to be displayed on label of container.** — Every manufacturer, importer or distributor of a formulation intended for sale shall display in indelible print mark on the label of the container of the formulation the maximum retail price of that formulation with the words «retail price not to exceed» preceding it and «local taxes extra» following it.

17. **Price list to be displayed at place of business.** — Every retailer shall display at a conspicuous part of the premises where he carries on his business, the price list furnished to him by the manufacturer or importer or distributor, as the case may be, in a manner so as to be easily accessible for consultation by any customer.

18. **Sale of split quantities of formulations.** — No dealer shall sell loose quantity of any formulations drawn from a bulk bottle pack of such formulation, at a price which exceeds the pro rata price of the formulation plus 5 per cent thereof:

Provided that nothing in this paragraph shall apply to any formulation compounded at the premises of the retailer.

19. **Retailer not to refuse sale.** — Subject to the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940), no dealer shall withhold from sale or refuse to sell any drug available with him to a customer wanting to purchase such drug.

20. **Calculation of manufacturer's or importer's price.** — The manufacturer's or importer's price, as the case may be, shall be calculated by deducting 20 per cent in the case of ethical drugs and 15 per cent in the case of non-ethical drugs from the retail price exclusive of excise duty and adding thereto the excise duty and local taxes payable if any, separately.

Explanation. — For the purposes of this paragraph, ethical drugs shall include all drugs covered by Schedule C, entries Nos. 1, 2, 3, 7, 8 and 9 of Schedule C(1), Schedule E, Schedule G, Schedule H and Schedule L to the Drugs and Cosmetics Rules, 1945, made under the Drugs and Cosmetics Act 1940 (23 of 1940), and non-ethical drugs shall mean all drugs other than the ethical drugs.

21. **Trade commission.** — The difference between the retail price and the manufacturer's or importer's price, as the case may be, shall be the trade commission which shall be apportioned as under: —

(1) not less than 12 per cent of the retail price for the retailer and not less than 8 per cent for all other intermediaries, in the case of ethical drugs, and

(2) not less than 10 per cent of the retail price for the retailer and not less than 5 per cent for all other intermediaries, in the case of non-ethical drugs.

22. **Maintenance and production for inspection of certain records of business.** — Every dealer shall maintain the cash memo or credit memo books, accounts and records of purchase or sale of drugs in such manner as to show separately the selling price, excise duty and local taxes payable, if any, and shall make available the said records of business for inspection of such officer of the Central Government or State Government who may be authorised by that Government in this behalf.

23. **Powers of entry, search and seizure.** — (1) Any officer of the Central Government or State Government authorised by that Government in this behalf may, with a view to securing compliance with this Order or to satisfy himself that this Order has been complied with, —

(i) enter and search any place;

(ii) seize any drug, along with the containers, packages or coverings in which the drug is found, in respect of which he suspects that any provision of this Order has been, is being or is about to be contravened, and thereafter take all measures, necessary for securing production of the drug, containers, packages or coverings so seized in a court of law for their safe custody pending such production;

(iii) seize any cash memo or credit memo books, accounts and records of purchase and sale of the drugs in respect of which he suspects that any provision of this Order has been or is being or is about to be contravened.

(2) The provisions of section 102 and section 103 of the Code of Criminal Procedure, 1898 (5 of 1898) relating to search or seizure shall, so far as may be, apply to searches and seizures under this paragraph.

24. **Review.** — Any person aggrieved by an Order made under paragraph 4, 5, 11, 12, 13 or 14 may apply to the Central Government for a review of that order and the Central Government may make such order thereon as it thinks fit.

SCHEDULE I

[*See paragraph 2(e)* and 3]

Essential Bulk Drugs

1. Vitamin A.
2. Vitamin B12.
3. Vitamin C.
4. Sulphadiazine.
5. (*i*) Penicillin Potassium G.
   (*ii*) Sodium Penicillin G.
   (*iii*) Procaine Penicillin.
   (*iv*) Potassium Penicillin V.
6. Streptomycin.
7. Chloramphenicol.
8. Tetracycline.
9. Amodiaquin.
10. Chloroquin Phosphate.
11. Iodo-Chlorophydroxy-quinoline.
12. Chlorpropamide.
13. Tolbutamide.
14. Insulin.
15. Isonicotinic Acid Hydrazide.
16. (*i*) Sodium Salt of Para Amino Salicylic Acid.
    (*ii*) Para Amino Salicylic Acid.
17. Tetanus Anti-toxin.
18. Prednisolone.

SCHEDULE II

Forms

[*See* paragraph 2 (f)]

Form No. 1

(*See* paragraph 5) (To be submitted in quintuplicate)

Cost Data for Bulk Drug

Name of the bulk drug Unit.

1. Installed capacity
   (This information may be given in terms of capacity *per month*, number of shifts per day and number of working days may also be given).
2. Actual operational capacity
   (This information may be given in terms of production *per month* based on the average of production during six representative months. Number of shifts per day and number of working days may also be stated).
3. Cost of installed plant and machinery including ancillary machinery ... Rs.
4. Cost of buildings ... ... Rs.
5. Requirements of raw material utilised for production *vide* (item 2) above

Name of raw material	Indigenous or imported	Unit (Kg./Litre, etc.)	Quantity	Rate	Total
(*i*)					
				Total	

6. Particulars of direct labour and supervision allocated on production *vide* (item 2) above

	Number employed	Days employed per month	Wage/Salary per month	Total
(*i*) Direct labour				
(*ii*) Supervision				
			Total ...	

7. Cost of services

	Per month			
	Unit	Quantity	Rate	Total
(*i*) Water				
(*ii*) Steam				
(*iii*) Power				
(*iv*) Child water				
(*v*) Compressed air				
(*vi*) Vacuum				
(*vii*) Other services (with details)				
			Total ...	

8. Overheads per month
   (*i*) Share of management ... Rs.
   (*ii*) Depreciation:
   (*a*) Plant and Machinery Rs.
   (*b*) Buildings ... ... Rs.
   (*iii*) Packing ... ... Rs.
   (*iv*) Sales promotion ... ... Rs.
   (*v*) Other overheads (with details) ... ... Rs.
9. Names and value of by-products obtained during manufacture ... ... Rs.
10. Royalty/know-how fee, if any, involved ... ... Rs.
11. Total cost of a month's production (items 5+6+7+8—9+ +10 above) ... ... Rs.
12. Cost of production *per unit*.
13. Any other information relevant to costing of _____ (name of the bulk drug)
14. Is the plant exclusively used for the manufacture of _____ (name of the bulk drug)
    or is it also used for the manufacture of other drugs? In the latter case, the names of drugs which are manufactured from the same plant or a part thereof and the capacity of each item may please be intimated.
15. Capital employed
    (to be certified by a chartered accountant).
    (*i*) Land
    (*ii*) Building
    (*iii*) Plant and Machinery
    (*iv*) Working capital
16. Present selling price of the drug per unit
17. National price in case the drug is used exclusively for own formulations.

Form No. 2

(*See* paragraph 8)

Form of price List (To be submitted in quintuplicate)

Form of Price List

Name Type	Composition (as printed on the label)	Specification of the pack	Manufacturer's price (exclusive of excise duty)	Excise duty Leviable	Retail price (inclusive of excise duty)
1		2	3	4	5

Form No. 3

(*See* paragraph 9)

(To be submitted in quintuplicate)

Information and details of calculations regarding retail price of formulation: —

PART I

1. (*a*) Name of the Company:
   (*b*) Address of the registered office:
   (*c*) Address of the factory:
2. Whether the manufacturer has opted for the alternative pricing scheme provided in paragraph 14 of the Drugs (Prices Control) Order, 1970.
3. Name of the formulation.

4. Nature of the pack:

(a) Type:

(Indicate tablet/capsule/liquid preparation like elixir, syrup, pediatric drops etc./ointments granulres/dry powder/injection like vial or ampoule etc.).

In case of tablets, please also indicate whether plain or coated and also the average weight of 100 tablets.

In case of capsules, please indicate whether they are soft or hard ones. In case of hard capsules such information as to whether they are with or without sealing band and also whether they are printed, may be indicated.

In case of liquid preparation and ointments (whether they are sterile preparations or not may be indicated).

(b) Composition of the drug (Please indicate the composition as indicated/to be indicated on the label).

(c) Specification of the pack:

(Specifically indicate the pack, *e.g.*, 10×10 tablets in cellophane strips/110 ml. in a glass bottle/1 ml+5 ampoules in a box etc.).

5. *(a)* Is the formulation claimed to be a new formulation as defined in paragraph 7 *(i) (a)* of the Drugs (Prices Control) Order, 1970. If so, furnish particulars in Part II.

(b) Is the formulation claimed to be a new formulation as defined in paragraph 7 *(i) (b)* of the Drugs (Prices Control) Order, 1970. If so, furnish particulars in Part III.

6. The manufacturer's prices and retail prices for which approval is sought: (Please furnish the basis of arriving at the prices in Part IV).

Specification of the pack	Manufacturing prices asked for	Retail prices asked for (inclusive of excise duty)
1	2	3

7. What was the percentage of sales of this formulation to the total turnover of your company during the last two years?

PART II

1. Has the formulation been evolved as a result of any research/special product development work? If so, give details of improvement effected and the improvement in therapeutic efficacy brought about thereby.

PART III

1. Does the formulation contain (as the active ingredient a new drug which is a product of) original research? If so, give the chemical and generic name of the drug.

2. Has there been any scientific publication about the aforesaid new drug? If so, enclose a copy of the publication.

3. Is the aforesaid new drug, the subject of any patent? If so, give details.

4. Has any developmental work/research been carried out of the evolution for the aforesaid new drug in India? If so, give details.

5. Is there any medical literature about the aforesaid new drug? If so, enclose copies.

6. Indicate the specific advantages of this new drug over any existing comparable drugs in the market.

7. Give details of the trials carried out to substantiate the claims.

8. Has approval under the Drugs and Cosmetics Act, 1940 (23 of 1940) if necessary been obtained for the introduction of this new drug?

9. Has this new drug been introduced in any country? If so, give particulars.

PART IV

(Cost and Price Data)

1. Specification of the pack:

2. *(a)* Batch size for which costing is shown: Number of tabs/litres/ /Kgs., etc.

(b) Number of finished packs actually obtained from sub-item *(a)* above;

(c) Number of finished packs that can be obtained theoretically from sub-item *(a)* above:

3. Consumption and cost of raw materials and pharmaceutical aids per batch as shown in item 2 *(a)* above:

Name of the raw materials	Unit Kg/Litres/ Million Unit etc.	Price per unit.	Quantity theoretically required per batch	Provision for averages if any	Total quantity consumed per batch	Total cost per batch
1	2	3	4	5	6(=4+5)	7(=3×6)
Imported						
1.						
2.						
3.						
etc.						
Indigenous						
1.						
2.						
3.						
etc.						
Total						Rs. X

Process loss as per norms Y

$$\text{4. M. C. (Materials Cost)} = \frac{X + Y}{\text{Number of packs as per item 2(c) above.}}$$

5. C. C. (Conversion Cost) (As per norms) = Rs.

6. ∴ M. C. + C.C. = Rs.

7. *Consumption and cost of packing materials per batch (Upto final despatchable stage Theoretical numbers of packs as in item 2 (c)*

Name of the Packing materials	Unit	Price per Unit	Quantities theoretically required for item 2(c)	Quantities actually required per batch	Price per batch
1	2	3	4	5	6
8. Total			Rs. A.		

9. (*i*) Process loss, if any Rs. B

(*ii*) Price per pack $= \frac{\text{Rs. A + B}}{\text{Theoretical Number of packs as in item 2(c)}} = \text{Rs. C}$

10. Packing Costs as per norms = Rs. D

11. ∴ P.C. = Rs. C & D

12. (*i*) ∴ M.C. + C.C. = Rs.
+ P.C. = Rs.
Total = Rs.

(*ii*) Mark-up (indicated the percentage) = Rs.

Total of above = Rs. Rs. R(Say)

(*iii*) Excise Duty = Rs. (E.D.)

13. Retail Price (inclusive of Excise Duty) = Rs.

14. Manufacturer's Price = Rs. (R — Trade commission + Excise Duty (Exclusing local taxes) = Rs.

15. Retail price before commencement of the Drugs (Prices Control) Order, 1970.

PART V

(To be filled by importer of drugs)

1. Name of the Drug:
2. Specification of the pack:
3. C.I.F. Cost per unit pack:
4. Import duty:
5. Clearing charges:
6. Landed Cost (items 3 + 4 + 5)
7. Mark-up (Indicate the percentage)
8. Repacking charges, if any (actuals or as per norms whichever is lower) (If actuals, details to be given).
9. Retail Price: X + E.D. (including local taxes payable if any)
10. Manufacturer's (Importer's) Price: = X—Trade Commission (×)

(×) Trade commission as applicable as per paragraph 21 of the Drugs (Prices Control) Order, 1970.

11. Retail price before the commencement of the Drugs (Prices Control) Order, 1970.

SCHEDULE III

(*See* paragraph 14) (To be submitted in quintuplicate)

Information to be furnished by the manufacturer, importer or dealer who has opted for the alternative scheme of pricing.

	1967-68 (Actuals)	1968-69 (Actuals)	1969-70 (Actuals)	1970-71 (Actuals) (upto the date of opting for the alternative scheme)	1970-71 (Estimated) for a period of 12 months commencing from the date of opting for the alternative scheme provided in paragraph 14 of the Drugs (Prices Control) Order, 1970	Percentage of increase of Col. 5 over Col. 3.
	1	2	3	4	5	6
1. Total turn-over of both bulk drugs and formulations.						
2. Turn-over of drugs.						
3. Turn-over of formulations of essential bulk drugs mentioned in Schedule I to the Drugs (Prices Control) Order, 1970						
4. Turn-over of other formulations ...						
5. Total turn-over of formulations (item 3 + item 4) ...						
6. Gross profit before taxes on total turn-over of item 1 ...						
7. Gross profit before taxes on the turn-over of formulations only item 5 ...						
8. Profit shown in item 7 as percentage of total turn-over of item 5 ...						

(*N. B.* — (1) The information above should be certified by a Chartered Accountant.

(2) Turn-over in case of bulk drugs includes captive consumption for the purpose of formulation etc."

[No. 17(7)/70-Ch. III]

M. RAMAKRISHNAYYA, Jt. Secy.

Order

New Delhi, the 18th May, 1970

S. O. 1873. — In pursuance of sub-para (I) of paragraph 4 of the Drugs (Prices Control) Order, 1970, the Central Government hereby fixes the prices shown in column (2) of the Table below as the maximum prices at which the essential bulk drugs included in Schedule I to the said Order at its commencement and specified in the corresponding entries in column (1) of the said Table shall be sold.

TABLE

Name of the essential bulk drug	Maximum selling price
(1)	(2)
1. Vitamin A	Rs. 391-00 per 1,000 mu.
2. Vitamin B 12	Rs. 100/- per gram.
3. Vitamin C	Rs. 72-70 per Kg.
4. Sulphadiazine	Rs. 58-89 per Kg.
5. (*i*) Penicillin Potassium G	Re. 0-40 per mega unit.
(*ii*) Sodium Penicillin G ...	Re. 0.50 per mega unit.
(*iii*) Procaine Penicillin ...	Re. 0.50 per mega unit.
(*iv*) Potassium Penicillin V	Re. 0-80 per mega unit.
6. Streptomycin	Rs. 295-00 per Kg.
7. Chloramphenicol	Rs. 357-66 per Kg.
8. Tetracycline	Rs. 850-00 per Kg.
9. Amodiaquin	Rs. 106-91 per Kg.
10. Chloroquin Phosphate ...	Rs. 259-53 per Kg.
11. Iodo-Chlorohydroxy-quinoline	Rs. 65-68 per Kg. (for production from basic stage) and Rs. 45-14 per Kg. (for others).
12. Chlorpropamide	Rs. 95-60 per Kg.
13. Tolbutamide	Rs. 74-16 per Kg.
14. Insulin	Rs. 4900 per mu.
15. Isonicotinic Acid Hydrazide	Rs. 126-16 Per Kg. if manufactured through indigenous picolines and Rs. 66-70 per Kg. (if manufactured through imported cyanopyridines).
16. Sodium Salt of para Amino Salicylic Acid	Rs. 31-28 per Kg.
17. Para Amino Salicylic Acid	Rs. 41-83 per Kg.
18. Prednisolone	Rs. 11946-21 per Kg.

Note.— The maximum selling prices specified in column (2) of the Table are exclusive of excise duty and local taxes payable, if any.

[No. 17(7)/70-Ch. III.]

M. RAMAKRISHNAYYA, Jt. Secy.

Notification

ILD/HS/2266/65

Government of India's, Ministry of Petroleum & Chemicals & Mines & Metals (Department of Petroleum & Chemicals) Drugs (Prices Control) Amendment Order, 1971, published in Part II, Section 3, Sub-Section (ii) of the Gazette of India, Extraordinary dated 11-1-1971, is hereby published for general public information.

By order and in the name of the Administrator of Goa, Daman and Diu.

D. N. Barua, Secretary, Public Health Department.

Panaji, 20th February, 1971.

GOVERNMENT OF INDIA

MINISTRY OF PETROLEUM AND CHEMICALS AND MINES AND METALS

Order

New Delhi, the 11th January, 1971

S. O. — In exercise of the powers conferred by section 3 of the Essential Commodities Act, 1955 (10 of 1955), the Central Government hereby makes the following order further to amend the Drugs (Prices Control) Order, 1970, namely: —

1. (1) This order may be called the Drugs (Prices Control) Amendment Order, 1971.

(2) It shall come into force on the date of its publication in the Official Gazette.

2. In the Drugs (Prices Control) Order, 1970, —

(i) in paragraph 2, —

(a) for clause (a), the following clause shall be substituted, namely: —

"(a) "bulk drug" means by unprocessed pharmaceutical chemical, biological and plant product or medicinal gas conforming to pharmacopoeial or other accepted standards which is used as such or after being processed into formulations and includes an essential bulk drug,"

(b) for clause (b), the following clause shall be substituted, namely: —

"(b) "dealer" means a person carrying on the business of purchase or sale of drugs whether as a wholesaler or a retailer and whether or not in conjunction with any other business and includes an agent of a dealer."

(c) for sub-clause (i) of clause (g), the following shall be substituted, namely: —

"(i) All bonafide ayurvedic (including Siddha) and Unani (Tibb) systems of medicines."

(d) clauses (i) and (l), shall be omitted;

(e) for clause (m), the following clause shall be substituted, namely: —

"(m) "price list" means the price list referred to in paragraphs 8, 10 and 14 and includes a supplementary price list."

(ii) in paragraph 5, —

(a) in sub-paragraph (1), for the words "manufacturer, importer or distributor" the words "manufacturer or importer" shall be substituted;

(b) after sub-paragraph (1), the following sub-paragraph shall be inserted, namely: —

"1. Notwithstanding anything contained in sub-paragraph (1), the Central Government may, after calling for such information as may be necessary, fix the selling price of any imported bulk drug having regard to its landed cost, handling charges, storage expenses, distribution costs, and reasonable return on capital invested;"

(iii) in paragraph 7, —

(a) for the opening brackets, letters, words and figures "(M. U.) referred to in paragraph 6 shall be the following, namely:— ", the following letters, words and figure shall be substituted, namely: —

"M. U. referred to in paragraph 6 includes the manufacturer's margin, promotional expenses, outward freight, distribution costs and the trade commission and shall be the following, namely:—";

(b) in clauses (i), (ii) and iii), before the figures "75", "100" and "150", respectively, the words "not exceeding" shall be inserted;

(c) in the two provisos, after the figure "75", the words "at least" shall be inserted;

(iv) in paragraph 8,

(a) for the words "manufacturer, importer or distributor", wherever they occur, the words "manufacturer or importer" shall be substituted;

(b) the words "the manufacturer's price" wherever they occur shall be omitted.

(v) in paragraph 9, for the words "manufacturer, importer or distributor", the words "manufacturer or importer" shall be substituted;

(vi) for paragraph 10, the following paragraph shall be substituted, namely: —

"10. Special provisions in respect of new packs, new formulations and new *manufacturers*.

(1) No manufacturer or importer shall market a new formulation or a new pack of his existing formulation except with the prior approval of the Central Government.

(2) For the purpose of applying for the approval of the Central Government, the manufacturer or importer, as the case may be, shall furnish information and details of calculations regarding retail price as in Form 3.

(3) The Central Government shall accord the approval subject to such modification as may be considered necessary having regard to the provisions contained in paragraphs 6, 7, 11 and 14 for the calculation of retail price within four months of the receipt of the application complete in all respects.

(4) The manufacturer or importer shall issue a price list or supplementary list in respect of the formulations or packs for which the approval is accorded by the Central Government within a fortnight of the receipt of approval by him. Where the approval is not accorded within the specified time-limit, the manufacturer or importer shall market the new formulation or new pack at the price calculated by him and shall issue price list or supplementary price list accordingly.

(5) The provisions of sub-paragraphs (1) to (4) shall apply to a new manufacturer or importer who markets his formulations for the first time".

(vii) for paragraph 11, the following paragraph shall be substituted: —

"11. Power of the Central Government to fix *retail prices of formulations.*

(1) If on the scrutiny of the price lists and the information and details of calculations furnished to it under paragraph 9, the Central Government is of the opinion that the retail price of any formulation has not been fixed in accordance with paragraph 6 or 7, it may fix the retail price of such formulation in accordance with the provisions of the said paragraphs and communiate the retail price so fixed to the manufacturer or importer, who shall amend the relevant price list and communicate the same to the dealers:

Provided that the Central Government shall have the power to adopt such mark-up within the ceilings mentioned in paragraph 7, as may be expedient in the public interest in the case of any particular formulation having regard to all relevant factors such as changes in the cost of raw materials, promotional expenses, volume of sales and the mark-up approved in the case of other similar or comparable formulations.

(2) The retail price of any formulation fixed by the Central Government under sub-paragraph (1) and the said amended price list shall come into force not later than fifteen days from the receipt of the aforesaid communication by the manufacturer or importer.

(3) The power under sub-paragraph (1) to fix the prices of formulations shall be exercised by the Central Government within four months from the date of receipt by it of the intimation of retail price for any formulation together with the information and details of calculations referred to in paragraph 9.

Provided that the said period of four months may be extended by the Central Government to six months in the case of formulations involving detailed examination.

Provided, however, that an intimation that the period has been extended to six months shall be sent by the Central Government before the expiry of the said period of four months to the manufacturer or importer concerned.

(4) Notwithstanding anything contained in sub-paragraph (1) and paragraphs 6, 7, 10, 13 and 14, the Central Government may either generally or in individual cases, by order, fix, in the public interest, the retail price of any formulation or class of formulations essential to the life of the community.

(5) The price fixed under sub-paragraph (4) shall be in force until altered or cancelled by the Central Government".

(viii) in paragraph 12, in sub-paragraph (1), for the words "manufacturer, importer or distributor", the words "manufacturer or importer" shall be substituted;

(ix) for paragraph 13, the following paragraph shall be substituted, namely: —

"13. *Revision of Prices.* — (1) The retail price of a formulation once fixed in accordance with the provisions of this Order shall not be increased except with the prior approval of the Central Government.

(2) Every application for increase in the retail price of a formulation shall be accompanied by information and details of calculations as required in Form 3.

(3) It shall be lawful for the Central Government to revise the retail price of any formulation *suo moto*.

(4) For the purpose of such revision, the Central Government may call for such information regarding cost structure of any formulation as it may consider necessary from any manufacturer or importer and fix the retail price in accordance with paragraphs 6 and 7 in which case the manufacturer or importer shall within fifteen days from the date of receipt of the Central Government's communication fixing the retail price of such formulation amend the price list and market the said formulation at the retail price fixed by the Central Government:

Provided that if the manufacturer or importer fails to furnish the required information within the time stipulated, the Central Government may on the basis of such information as is available with it, fix the retail price of the said formulation and communicate the same to the manufacturer or importer and the manufacturer or importer shall within 15 days of the receipt of the aforesaid communication revise the price list accordingly, and market the formulation at the retail price so fixed".

(x) for paragraph 14, the following paragraph shall be substituted; namely: —

"14. *Alternative scheme of pricing.* — (1) Notwithstanding anything contained in the other provisions of this Order, the manufacturer or importer may, if he so chooses, submit to the Central Government for approval a scheme of prices covering all of the formulations marketed by him so that the overall gross profit before tax does not exceed 15 of the sales turnover as estimated by him and submit the price list resulting therefrom, alongwith such other information as is required in Schedule III for the purpose:

Provided that the scheme shall be subject to the following conditions, namely: —

(i) the formulations based on the essential bulk drugs shall be priced in accordance with the provisions of paragraphs 6 and 7;

(ii) the formulations based on the bulk drugs other than the essential bulk drugs shall be priced in accordance with the formula in paragraph 6, in such a way that the mark-up in any individual case does not exceed 150 or such lower or higher mark-up as the Central Government may permit in any case having regard to the circumstances of that case;

(iii) the manufacturer or importer shall, on choosing the scheme, undertake and maintain separate accounts for formulations based on essential bulk drugs and the formulations based on other bulk drugs, and submit them for scrutiny in such manner as may be specified by the Central Government;

(iv) in case the actual gross profit before tax for any particular year as shown in the audited accounts of the manufacturer or importer exceeds 15% of the sales turn-over of the year, as certified by the auditor, the excess shall be funded separately and shall not be utilized, for distribution of dividends but shall be utilized with the prior approval of the Central Government, for any of the following purposes, namely: —

(i) research and development expenditure;

(ii) adjustment against future profits or losses;

(iii) such other purposes as may be specified by the Central Government from time to time.

Explanation. — "the formulation based on the essential bulk drugs" means the formulation which contains one or more of the essential bulk drugs as major therapeutic ingredient.

(2) The option referred to in sub-paragraph (1) shall be exercised and the price lists under the alternative pricing scheme accompanied by information and details of calculations regarding retail price as required in Form No. 3 shall be submitted to the Central Government by the manufacturer or importer, as the case may be, within two months of the commencement of this Order;

Provided that the Central Government may for sufficient cause, either generally or in individual cases, extend the said period of two months to such further period or periods as it may deem fit so however, that the period or periods so extended shall not exceed four months from the date of commencement of this Order in any case.

(3) Pending the decision of the Central Government on the price lists submitted to it under sub-paragraph (2), the manufacturer or importer may market his formulations as per price lists submitted by him under the said sub-paragraph.

Provided that in any case where the price for any formulation calculated in accordance with the provisions of sub-paragraph (1) is higher than the price prevailing on the 15th May, 1970, for such formulation, then until such time the decision of the Central Government on the price list submitted under sub-paragraph (2) is received, such formulation shall be marketed only at the price prevailing on the date aforesaid.

(4) The Central Government shall have the power to approve or modify the price of any

formulation included in the price list submitted to it under sub-paragraph (2) and shall communicate its decision to the manufacturer or importer not later than the 31st December, 1970:

Provided that in cases where the communications regarding such decisions are not issued by the aforesaid date, the price lists submitted under sub-paragraph (2) shall be deemed to have been approved by the Central Government and shall be deemed to be valid price lists for the purpose of this paragraph.

(5) For the purpose of approval or modification of the price of any formulation included in the price list submitted to it under sub-paragraph (2) it shall be lawful for the Central Government to take into consideration all relevant factors such as product-mix, material costs, the number and nature of specialised formulations, if any, export performance during the preceding three years, amount and nature of expenditure on research, trend of gross profits before tax during the immediately preceding three years of the manufacturer and the prices approved for similar or comparable formulation of other manufacturers or importers as the case may be.

(6) The prices of the formulations under this paragraph shall take effect within fifteen days of the receipt of the communication regarding decision of the Central Government relating to approval or modification of the price of any formulation by the manufacturer or importer.

(7) Where the Central Government modifies the price of any formulation, it shall communicate in writing the reasons for such modification to the manufacturer or importer unless such modification follows from the revision made by the manufacturer or importer himself in consultation with the Central Government.

(8) The provisions of paragraph 13 shall so far as may be, apply to revision of prices of formulations fixed under this paragraph.

(9) The provisions of paragraph 10, shall so may be, apply to new packs of existing formulations and new formulations to be marketed by a manufacturer or importer who opts for the alternative scheme of pricing.

(10) The option once exercised by the manufacturer or importer shall not be changed without the previous approval of the Central Government.

(11) If any difficulty arises in giving effect to the provisions of this paragraph, the Central Government may, from time to time, issue such orders, directions or instructions, not inconsistent with the provisions of this Order as appear to it to be necessary or expedient for the removal of such difficulty".

(xi) for paragraph 15, the following paragraph shall be substituted, namely:—

"*Control of sale prices of formulations.* — No retailer shall sell any formulation to a customer at a price exceeding the retail price of that formulation in the price list approved by the Central Government plus the local taxes if any payable.

Explanation. — For the purpose of this paragraph local taxes shall include sales tax actually paid by the retailer under the law in force in a particular area";

(xii) in paragraph 19, in the title for the word "Retailer", the word "Dealer" shall be substituted;

(xiii) paragraph 20 shall be omitted;

(xiv) for paragraph 21, the following paragraph shall be substituted, namely: —

"21. *Price to the wholesaler and retailer.* —(1) No manufacturer, importer or distributor shall sell a formulation to a wholesaler unless otherwise permitted under the provisions of this order or any order made thereunder at a price higher than the retail price minus 14% thereof in the case of ethical drugs and retail price minus 12% thereof in the case of non-ethical drugs.

(2) No manufacturer, importer, distributor or wholesaler shall sell a formulation to a retailer unless otherwise permitted under the provisions of this order or any order made thereunder at a price higher than the retail price minus 12% thereof in the case of ethical drugs and retail price minus 10% thereof in the case of non-etical drugs.

Explanation: For the purpose of this paragraph, ethical drugs shall include all drugs covered by Schedule C, entries Nos. 1, 2, 3, 7, 8 and 9 of Schedule C(1), Schedule E, Schedule G, Schedule H and Schedule L to the Drugs and Cosmetics Rules, 1945, made under the Drugs and Cosmetics Act, 1940 (23 of 1940) and non-ethical drugs shall mean all drugs other than the ethical drugs.

(3) Notwithstanding anything contained in sub-paragraphs (1) and (2), the Central Government may either generally or in individual cases, by order fix, in the public interest, the price to the wholesaler or retailer in respect of any formulation referred to in sub-paragraph (4) of paragraph 11.

(xv) in paragraph 22, the words "in such manner as to show separately, the selling price, and local taxes payable if any" shall be omitted.

(xvi) in Schedule II, (a) for form No. 2, the following shall be substituted, namely: —

"Form No. 2.

(see paragraphs 8, 10 and 14)

Form of price list (to be submitted in quintuplicate)

FORM OF PRICE LIST

Name of the formulation	Composition (main ingredients to be given)	Specification of the pack	Excise Duty	Price to the retailer (inclusive of excise duty)	Retail price (inclusive of excise duty)
1	2	3	4	5	6

(b) in form 3, part I, for item 6, the following shall be substituted, namely: —

«6. The price to the retailer and retail price for which approval is sought (please furnish the basis for arriving at the prices in Part IV).

Specification of the pack	Price to the retailer	Retail price inclusive of excise duty
1	2	3

(c) in form 3, for part IV, the following shall be substituted, namely: —

«PART IV

(Cost and Price Data)

1. Specification of the pack:

2. (a) Batch size for which costing is shown: Numbers of tabs/litres/kgs. etc.

(b) Number of finished packs actually obtained from sub-item (a) above;

(c) Number of finished packs that can be obtained theoretically from sub-item (a) above.

3. Consumption and cost of raw materials and pharmaceutical aids per batch as shown in item 2(a) above.

Names of the raw materials	Unit Kg/Litre/ /Million/ /Unit etc.	Price per unit	Quantity theoretically required per batch	Provision for overages if any	Total quantity consumed per batch	Total cost per batch
1	2	3	4	5	6(=4+5)	7(=3×6)
Imported:						
1.						
2.						
3.						
etc.,						
Indigenous:						
1.						
2.						
3.						
etc.						
Total						Rs. x

Process loss as per norms $\frac{Y}{X+Y}$

4. M.C. (Materials Cost) $= \frac{X+Y}{\text{Number of packs as per item 2(c) above}}$

5. C. C. (Conversion Cost) (As per norms)=Rs.

6. ∴ M. C.+C. C. =Rs.

7. Consumption and cost of packing materials per batch (upto *final despatchable stage)*.

Theoretical numbers of packs as in item 2(c)

Name of the packing materials	Unit	Price per unit	Quantities theoretically required for item 2(c)	Price per batch
1	2	3	4	5(=3×4)
8. Total				Rs.

9. (i) Process loss, if any (not to exceed the prescribed norms) Rs. B

(ii) Price per pack $= \frac{\text{Rs. A+B}}{\text{Theoretical Number of packs as in item 2(c)}} =$

=Rs. C(=Rs. R+B).

10. Packing expenses as per norms. =Rs. D

11. ∴ P. C. =Rs. C+D

12. (i) ∴ M. C.+C. C.=Rs.
+P. C.=Rs.
Total =Rs.

(ii) Mark-up (indicate the percentage)=Rs.

Total of above =Rs. Rs. R (Say)

(iii) Excise Duty =Rs. (E. D.)

13. Retail Price (inclusive of Excise Duty)—Rs. (R+ED).

14. Price to the retailer (see para 21)=Rs.

15. Retail price inclusive of excise duty before commencement of the Drugs (Price Control) Order, 1970.

(d) in form 3, for part V, the following shall be substituted, namely: —

«PART V

(To be filled by importer of drugs)

1. Name of the Drug.
2. Specification of the pack:
3. C I. F. Cost per unit pack:
4. Import duty:
5. Clearing charges:
6. Landed Cost (items 3+4+5):
7. Repacking charges if any, (actuals or as per norms whichever is lower; if actuals, details to be given):
8. Total ex-factory cost (6+7):
9. Mark-up adopted (indicate the percentage):
10. Excise duty payable:
11. Retail price inclusive of excise duty (8+9+10):
12. Retail price inclusive of excise duty before the commencement of the Drugs (Price Control) Order, 1970».

No. 17(82)/70-Ch.III

M. RAMAKRISHNAYYA
Joint Secretary to the Govt. of India.

Labour and Information Department

Mormugao Port Trust

—

Notification

MPT/IGA(E.1016)/71

In terms of Section 124(2) of the Major Port Trusts Act, 1963, the following amendment to the draft Mormugao Port Employees (Reimbursement of Tuition Fees) Regulations 1969 notified in the Government Gazette Nos. 39 and 40 (Series I) dated 26-12-69 and 1-1-70 respectively, as adopted by the Board is hereby published: —

Substitute the following for the existing Regulation 4:

"4. *Rate of Allowance.*

Reimbursement of tuition fees will be made at rates not exceeding those approved by the Government of the area for Government Schools. In States where education is free and no fees have been prescribed for schools run by the State Government, reimbursement of fees charged by Government aided and recognised unaided schools and also Departmental Schools except those meant for blind, deaf and dumb students shall be made with effect from 1-6-1970 at the rates actually paid subject, however, to the following ceilings: —

Class I to Class VIII	At the rate of Rs. 5/- per month.
Class IX	At the rate of Rs. 6/- per month.
Class X	At the rate of Rs. 7/- per month.
Class XI	At the rate of Rs. 8/- per month.

For the purpose of reimbursement of tuition fees, a college run by a University shall be treated at par with 'aided School' and the fees actually paid will be reimbursed. A college affiliated to a University will, on the other hand, be treated like a recognised unaided institution and the tuition fees actually paid in such a college that may be reimbursed shall not exceed the fees prescribed by a University with which it is affiliated".

By order,

Shivakumar Dhindaw
Secretary

Mormugao, 6th January, 1971.

(2nd time)

———

Notification

MPT/IGA(E.806)/71

As required under Section 124(2) of the Major Port Trusts Act, 1963, the following amendments to the Mormugao Port Employees (Contributory Provident Fund) Regulations, 1965 and Mormugao Port Employees (General Provident Fund) Regulations, 1964, adopted by the Board of Trustees are hereby published: —

I. Substitute the following for the existing Sub-Regulation 13(1)(c) including the two provisos thereto of Mormugao Port Employees (Contributory Provident Fund) Regulations, 1965.

"(c) to pay obligatory expenses on a scale appropriate to the subscriber's status which by customary usage the subscriber has to incur in connection with marriages, funerals or other ceremonies".

II. Substitute the following for the existing Sub-Regulation 13(1)(c) including the two provisos thereto of Mormugao Port Employees (General Provident Fund) Regulations, 1964.

"(c) to pay obligatory expenses on a scale appropriate to the subscriber's status which by customary usage the subscriber has to incur in connection with marriages, funerals or other ceremonies".

III. Insert the following as sub-regulation (1A) after sub-regulation 1 of Regulation 13 of the Mormugao Port Employees (Contributory Provident Fund) Regulations, 1965:

"(1A) The appropriate sanctioning authority may, in special circumstances, sanction the payment to any subscriber of an advance if he is satisfied that the subscriber concerned requires the advance for reasons other than those mentioned in sub-regulation (1)".

IV. Insert the following as sub-regulation (1A) after sub-regulation 1 of Regulation 13 of the Mormugao Port Employees (General Provident Fund) Regulations, 1964.

"(1A) The appropriate sanctioning authority may, in special circumstances, sanction the payment to any subscriber of an advance, if he is satisfied that the subscriber concerned requires the advance for reasons other than those mentioned in sub-regulation (1)".

V. Add the following proviso to the sub-regulation (2) of Regulation 24 of the Mormugao Port Employees (Contributory Provident Fund) Regulations, 1965.

"Provided that where no manager has been appointed and the person to whom the sum is payable is certified by a Magistrate to be a lunatic, the payment shall under the orders of the Collector, be made in terms of sub-section (1) of Section 95 of the Indian Lunacy Act, 1912, to the person having charge of such lunatic and the Accounts Officer shall pay only the amount which he thinks fit to the person having charge of the lunatic and the surplus, if any, or such part thereof, as he thinks fit, shall be paid for the maintenance of such members of the lunatic's family as are dependent on him for maintenance".

VI. Add the following proviso to the sub-regulation (2) of Regulation 23 of the Mormugao Port Employees (General Provident Fund) Regulations, 1964.

"Provided that where no manager has been appointed and the person to whom the sum is payable is certified by a Magistrate to be a lunatic, the payment shall, under the orders of the Collector, be made in terms of Sub-Section

(1) of Section 95 of the Indian Lunacy Act, 1912, to the person having charge of such lunatic and the Accounts Officer shall pay only the amount which he thinks fit to the person having charge of the lunatic and the surplus, if any, or such part thereof as he thinks fit, shall be paid for the maintenance of such members of the lunatic's family as are dependent on him for maintenance".

By order,

Shivakumar Dhindaw
Secretary

Mormugao, 6th January, 1971.

(2nd time)

Government Press

Notice

The subscribers to the Official Gazette are kindly reminded that their present subscription term ends on the 31st March 1971, which is the close of the financial year.

In case they wish to continue to be subscribers for the ensuing financial year of 1971-72 they have to renew their subscriptions from 1st April, next.

The subscriptions can also be opened for half-year i. e. from 1st April, 1st July or 1st October or for any quarter beginning on 1st April, 1st July, 1st October or 1st January.

Renewal of subscription should be effected on or before 31st March, 1971, in order to avoid interruption in the dispatch of copies of the Gazette. It should be noted that subscribers are entitled to receive copies of the Gazette only from the date the subscription rates have actually been paid.

The subscription charges are accepted either in cash, money order or demand draft on State Bank of India, Panaji, in favour of the Assistant Manager, Government Printing Press, Panaji, Goa, only. Remittances by cheques or any other form of payment will not be accepted.

SUBSCRIPTION RATES
(Including postage)

	Yearly	Half Yearly	Quarterly
	Rs.	Rs.	Rs.
All 3 Series	43-00	25-50	13-75
I Series	23-00	13-50	9-75
II Series	19-00	11-50	8-75
III Series	23-00	13-50	9-75

GOVT. PRINTING PRESS — GOA
(Imprensa Nacional — Goa)
PRICE — Rs. 1-87 Ps.